Wellgistics Health 计划收购 WellCare Today 及其专有的三星 Galaxy Watch 护理监测项目,以此加速其新近宣布的远程患者监测(RPM)、远程治疗管理(RTM)和慢性病管理(CCM)试点项目的数字健康业务拓展 ACN Newswire

Wellgistics Health 计划收购 WellCare Today 及其专有的三星 Galaxy Watch 护理监测项目,以此加速其新近宣布的远程患者监测(RPM)、远程治疗管理(RTM)和慢性病管理(CCM)试点项目的数字健康业务拓展

重点:WellCare Today 拥有成熟的 RPM、RTM 和 CCM 基础设施,并具备可穿戴技术集成和联网监测解决方案此次整合预计将把 Wellgistics Health 近期与 Kare Clinicals 联合推出的 MSO 计划,与其覆盖 6,500 多家独立药房的网络相结合拟建平台旨在提升患者参与度、用药依从性、远程监测及纵向护理协调能力拟议交易估值约为 1,500 万美元该战略举措旨在为参与的药房和医疗服务提供者创造额外的临床收入机会佛罗里达州坦帕市, 2026年5月15日 - (亚太商讯 via SeaPRwire.com) - 领先的医疗健康技术与药品分销公司 Wellgistics Health, Inc.(纳斯达克代码:WGRX)(以下简称“Wellgistics”或“公司”)今日宣布,已签署一份收购 WellCare Today 的非约束性意向书(“LOI”)。拟议的交易结构包括300万美元的现金支付,剩余部分将通过以优先股形式发放的基于业绩的延期付款来结算。WellCare Today是一家专注于慢性病管理(“CCM”)、远程患者监测(“RPM”)及远程治疗监测(“RTM”)项目的医疗科技与远程监测公司。该公司提供HealthAssist®——一款嵌入独立三星Galaxy Watch设备的先进远程健康监测平台,该平台是其更广泛的“健康监测与紧急支援生态系统”的重要组成部分。该平台通过符合 Medicare 报销标准的 RPM 和 RTM 项目,能够对心率、血氧水平、体温、睡眠模式、活动追踪以及患者自报的用药依从性等关键健康指标进行被动、持续的监测。无法保证任何特定的患者、医疗服务提供者、药房、服务、设备或工作流程均符合报销资格。根据拟议的交易架构,Wellgistics Health计划将WellCare Today的HealthAssist®平台及其RPM、RTM和CCM能力,与公司近期宣布的MSO试点合作项目进行整合。该合作涉及Kare PharmTech, LLC旗下子公司Kare Clinicals,以及其覆盖超过6,500家独立药房的网络。整合后的基础设施旨在利用互联可穿戴技术和远程监测基础设施,在医疗服务提供者和药房渠道之间支持可扩展的患者参与、用药依从性计划、纵向监测项目、慢性病管理以及增强的护理协调工作流程。拟议交易还预计将为Wellgistics药房网络内的参与药房创造机会,使其能够参与与RPM、RTM和CCM计划相关的临床服务项目,同时使医疗服务提供者能够访问可扩展的护理协调、监测和报销基础设施。双方认为,此次拟议的合作有望通过技术驱动的互动与远程监测平台,构建一个更紧密互联的医疗生态系统,将患者、药房、医疗服务提供者、可穿戴技术及纵向护理协调服务有机结合。该意向书不具约束力,拟议交易的完成仍需满足惯例尽职调查、最终协议的谈判与签署、董事会批准、融资安排及其他惯例交割条件。无法保证最终协议将得以签署,亦无法保证拟议交易将按当前设想完成,甚至可能无法完成。关于 Wellgistics Health, Inc.Wellgistics Health(纳斯达克代码:WGRX)是一家健康信息技术领域的领导者,其将专有的药房配药优化人工智能平台 EinsteinRx™ 整合至基于区块链的智能合约平台 PharmacyChain™ 中,以优化处方药配药流程。其集成平台连接了超过 6,500 家药房和 200 多家制造商,提供批发分销、数字处方路由、直接送达患者以及由人工智能驱动的枢纽服务,例如资格验证、患者入网、用药依从性支持、事前授权和现金支付履约,旨在改善患者在处方药生态系统中的可及性并提高透明度。关于 WellCare Today, LLCWellCare Today 是一家医疗科技公司,提供 HealthAssist® 服务——这是一个先进的远程健康监测平台,内置于独立的三星 Galaxy Watch 设备中,是其全面健康监测与紧急支援生态系统的重要组成部分。HealthAssist® 能够对关键健康指标进行被动、持续的监测,包括每小时心率、每小时血氧水平、体温、每日步数、睡眠模式以及用户自报的用药依从性。HealthAssist® 与 Medicare 可报销的远程治疗监测 (RTM) 和远程患者监测 (RPM) 项目集成,提供了一种经济实惠且可扩展的解决方案,旨在为老年人及慢性病患者提供支持。所有 RPM、RTM、CCM 及相关护理协调服务,均应由持有适当执照的医疗服务提供者及参与机构,依据适用的联邦和州医疗保健法律、Medicare 及支付方要求、反欺诈与反滥用法律、隐私及数据安全要求以及专业执业规则进行提供、监督、记录和计费。本公司不通过本新闻稿提供医疗建议,参与任何项目均须符合适用的临床、合同、监管及报销要求。前瞻性陈述本新闻稿包含《1995年私人证券诉讼改革法案》及其他适用联邦证券法所界定的前瞻性陈述。前瞻性陈述包括但不限于关于拟收购WellCare Today, LLC的陈述; 任何交易的预期结构、估值、对价、优先股条款及潜在时间安排;本公司完成尽职调查、协商并签署最终协议、获得董事会批准、筹集资金、满足交割条件并完成拟议交易的能力;WellCare Today的平台、技术、人员、项目及工作流程与本公司的医疗服务组织(MSO)、药房网络、医疗服务提供者及医疗技术计划的潜在整合; HealthAssist®及相关可穿戴技术在远程患者监测(RPM)、远程治疗管理(RTM)、慢性病管理(CCM)、用药依从性、患者参与及护理协调项目中的潜在应用;药房、医疗服务提供者、患者及支付方的潜在参与;RPM、RTM、CCM或相关服务潜在的报销可用性;潜在的收入机会;以及本公司的增长战略、业务计划和未来业绩。前瞻性陈述通常包含“可能”、“可能”、“将会”、“应该”、“预期”、“预计”、“相信”、“打算”、“计划”、“预测”、“估计”、“潜在”、“机会”、“目标”、“预测”、“继续” “将”及类似表述。此类陈述基于当前的预期、假设和估计,并受风险和不确定性影响,其中许多因素超出公司的控制范围。可能导致实际结果与预期存在重大差异的重要因素包括但不限于:各方未能签订最终协议的风险;意向书被终止或未能促成交易完成的风险; 拟议估值、对价、优先股条款或其他交易条款发生重大变更的风险;未能以可接受条款或完全无法获得所需融资、董事会批准、第三方批准或监管批准的风险;根据最终交易条款,可能需要获得纳斯达克股东批准或满足其他纳斯达克要求的风险;所收购的技术、项目或业务未能成功整合的风险; 预期收益、协同效应、供应商采用率、药房参与度、患者参与度、报销或收入机会未能实现的风险;与医疗保健法规、联邦医疗保险(Medicare)及支付方要求、反欺诈与滥用法规、隐私及数据安全要求、专业执业规则、设备性能、第三方技术依赖性以及报销政策变更相关的风险;以及本公司向美国证券交易委员会提交的文件中所述的其他风险和不确定性。前瞻性陈述仅反映其作出之日的观点,除适用法律要求外,本公司不承担更新或修订任何前瞻性陈述的义务。Wellgistics 媒体与投资者联系媒体:media@wellgisticshealth.com 投资者关系:IR@wellgisticshealth.com 来源:Wellgistics Health, Inc. Copyright 2026 亚太商讯 via SeaPRwire.com. All rights reserved. www.acnnewswire.com
More
Wellgistics Health Accelerates Digital Health Expansion of its Newly Announced RPM, RTM and CCM Pilot with Planned Acquisition of WellCare Today and its Proprietary Samsung Galaxy Watch Care Monitoring Program ACN Newswire

Wellgistics Health Accelerates Digital Health Expansion of its Newly Announced RPM, RTM and CCM Pilot with Planned Acquisition of WellCare Today and its Proprietary Samsung Galaxy Watch Care Monitoring Program

Highlights:WellCare Today brings established RPM, RTM and CCM infrastructure with wearable technology integrations and connected monitoring solutionsCombination expected to integrate Wellgistics Health recently announced MSO initiative with Kare Clinicals and its network of 6,500+ independent pharmaciesProposed platform designed to enhance patient engagement, medication adherence, remote monitoring and longitudinal care coordinationProposed transaction valued at approximately $15 millionStrategic initiative intended to create additional clinical revenue opportunities for participating pharmacies and providersTAMPA, FLA., May 15, 2026 - (ACN Newswire via SeaPRwire.com) - Wellgistics Health, Inc. (NASDAQ:WGRX) ("Wellgistics" or the "Company"), a leading healthcare technology and pharmaceutical distribution company, today announced that it has executed a non-binding letter of intent ("LOI") to acquire WellCare Today. The proposed transaction structure includes a structured cash payment of $3 million, with the balance to be satisfied through a performance-based earnout issued in preferred stock.WellCare Today is a healthcare technology and remote monitoring company focused on chronic care management ("CCM"), remote patient monitoring ("RPM"), and remote therapeutic monitoring ("RTM") programs. The company delivers HealthAssist®, an advanced remote health monitoring platform embedded within standalone Samsung Galaxy Watch devices as part of its broader Health Monitoring & Emergency Support Ecosystem. The platform enables passive, continuous monitoring of key health metrics including heart rate, blood oxygen levels, temperature, sleep patterns, activity tracking, and self-reported medication adherence through Medicare-reimbursable RPM and RTM programs. No assurance can be given that any particular patient, provider, pharmacy, service, device or workflow will qualify for reimbursement.Under the proposed transaction structure, Wellgistics Health intends to integrate WellCare Today's HealthAssist® platform and RPM, RTM and CCM capabilities with the Company's recently announced MSO pilot collaboration involving Kare Clinicals, a division of Kare PharmTech, LLC, as well as its network of more than 6,500 independent pharmacies. The combined infrastructure is intended to support scalable patient engagement, medication adherence initiatives, longitudinal monitoring programs, chronic disease management, and enhanced care coordination workflows across provider and pharmacy channels utilizing connected wearable technologies and remote monitoring infrastructure.The proposed transaction is also expected to create opportunities for participating pharmacies within the Wellgistics Pharmacy Network to engage in clinical service programs associated with RPM, RTM and CCM initiatives, while enabling providers to access scalable care coordination, monitoring, and reimbursement infrastructure. The companies believe the proposed collaboration may establish a more connected healthcare ecosystem aligning patients, pharmacies, providers, wearable technologies, and longitudinal care coordination services through technology-enabled engagement and remote monitoring platforms.The LOI is non-binding, and completion of the proposed transaction remains subject to customary due diligence, negotiation and execution of definitive agreements, board approvals, financing considerations, and other customary closing conditions. There can be no assurance that a definitive agreement will be executed or that the proposed transaction will be completed as currently contemplated, or at all.About Wellgistics Health, Inc.Wellgistics Health (NASDAQ:WGRX) is a health information technology leader integrating its proprietary pharmacy dispensing optimization artificial intelligence platform EinsteinRx™ into its blockchain-enabled smart contracts platform PharmacyChain™ to optimize the prescription drug dispensing journey. Its integrated platform connects more than 6,500 pharmacies and 200+ manufacturers, offering wholesale distribution, digital prescription routing, direct-to-patient delivery, and AI-powered hub services such as eligibility verification, onboarding, adherence support, prior authorization, and cash-pay fulfillment designed to improve patient access and transparency across the prescription ecosystem.About WellCare Today, LLCWellCare Today is a healthcare technology company delivering HealthAssist®, an advanced remote health monitoring platform embedded within standalone Samsung Galaxy Watch devices as part of its comprehensive Health Monitoring & Emergency Support Ecosystem. HealthAssist® enables passive, continuous monitoring of key health metrics including hourly heart rate, hourly blood oxygen levels, temperature, daily steps, sleep patterns, and self-reported medication adherence. Integrated with Remote Therapeutic Monitoring (RTM) and Remote Patient Monitoring (RPM) programs reimbursable by Medicare, HealthAssist® delivers an affordable, scalable solution designed to support seniors and individuals managing chronic health conditions.All RPM, RTM, CCM and related care-coordination services are expected to be furnished, supervised, documented and billed by appropriately licensed providers and participating entities in accordance with applicable federal and state healthcare laws, Medicare and payor requirements, fraud and abuse laws, privacy and data-security requirements, and professional practice rules. The Company does not provide medical advice through this press release, and participation in any program will be subject to applicable clinical, contractual, regulatory and reimbursement requirements.Forward-Looking StatementsThis press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and other applicable federal securities laws. Forward-looking statements include, without limitation, statements regarding the proposed acquisition of WellCare Today, LLC; the anticipated structure, valuation, consideration, preferred-stock terms and potential timing of any transaction; the Company's ability to complete due diligence, negotiate and enter into definitive agreements, obtain board approvals, secure financing, satisfy closing conditions and complete the proposed transaction; the potential integration of WellCare Today's platform, technology, personnel, programs and workflows with the Company's MSO, pharmacy network, provider and healthcare technology initiatives; the potential use of HealthAssist® and connected wearable technologies in RPM, RTM, CCM, medication adherence, patient engagement and care-coordination programs; the potential participation of pharmacies, providers, patients and payors; the potential availability of reimbursement for RPM, RTM, CCM or related services; the potential creation of revenue opportunities; and the Company's growth strategy, business plans and future performance.Forward-looking statements may be identified by words such as "may," "could," "would," "should," "expect," "anticipate," "believe," "intend," "plan," "project," "estimate," "potential," "opportunity," "target," "forecast," "continue," "will" and similar expressions. These statements are based on current expectations, assumptions and estimates and are subject to risks and uncertainties, many of which are beyond the Company's control. Important factors that could cause actual results to differ materially include, but are not limited to: the risk that the parties do not enter into definitive agreements; the risk that the letter of intent is terminated or does not result in a completed transaction; the risk that the proposed valuation, consideration, preferred-stock terms or other transaction terms change materially; the risk that required financing, board approvals, third-party approvals or regulatory approvals are not obtained on acceptable terms or at all; the risk that Nasdaq shareholder approval or other Nasdaq requirements may apply depending on the final transaction terms; the risk that acquired technologies, programs or operations are not successfully integrated; the risk that anticipated benefits, synergies, provider adoption, pharmacy participation, patient engagement, reimbursement or revenue opportunities are not realized; risks associated with healthcare regulation, Medicare and payor requirements, fraud and abuse laws, privacy and data-security requirements, professional practice rules, device performance, third-party technology dependencies and changes in reimbursement policy; and other risks and uncertainties described in the Company's filings with the U.S. Securities and Exchange Commission.Forward-looking statements speak only as of the date they are made, and the Company undertakes no obligation to update or revise any forward-looking statements, except as required by applicable law.Wellgistics Media & Investor ContactMedia: media@wellgisticshealth.comInvestor Relations: IR@wellgisticshealth.comSOURCE: Wellgistics Health, Inc. Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com
More

Asset Value Investors (AVI) urges the dismissal of two directors at Wacom

LONDON, May 14, 2026 - (ACN Newswire) - Asset Value Investors Limited (“AVI”) has submitted shareholder proposals on one of AVI Japan Opportunity Trust’s (“AJOT”) portfolio companies, Wacom Corporation (TSE: 6727, “Wacom”) calling for board changes ahead of Wacom’s upcoming Annual General Meeting in June. AVI, Wacom’s largest shareholder on behalf of all the portfolios it manages, is seeking the dismissal of two directors and the appointment of one external director. Alongside these proposals, AVI has disclosed additional material on its Wacom campaign, including a detailed presentation on an updated dedicated website (www.DrawWacomsFuture.com). Since initiating its investment in Wacom in August 2021, AVI has sought various forms of engagement aimed at enhancing the company’s long-term corporate value as Wacom’s largest shareholder. However, the Branded Business, one of Wacom’s principal business segments, fell into loss from FY2023/3 onwards, and business growth has stalled amid the implementation of large-scale restructuring measures. Furthermore, AVI has serious concerns regarding Wacom’s governance framework in light of the recently announced inappropriate acquisition of a company represented by one of Wacom’s own outside directors, despite the absence of tangible business synergies with Wacom, as well as the improper use of corporate resources, including the provision of preferential treatment to the children of the company representative director, Mr Ide. In light of these circumstances, AVI, as the company’s largest shareholder and a long-term investor on behalf of all the portfolios it manages, publicly launched a campaign last year to support sustainable improvements in corporate value. This year, AVI has decided to publish additional materials and submit shareholder proposals at the upcoming annual general meeting, as follows: - Appointment of one outside director - Dismissal of two directors (the Representative Director and one outside director) Kaz Sakai, Head of Japan Research at AVI, commented as follows: “Wacom has demonstrated serious deficiencies in governance oversight. These include the acquisition by Wacom of a loss-making company represented by Mr Nakajima, one of its own external directors, for more than ten million dollars, the subsequent transfer of Mr Nakajima into an internal director role, and conduct by Mr Ide, Wacom’s Representative Director and CEO, that can only reasonably be viewed as a conflation of personal and corporate interests, together with a board that has tolerated such behaviour.” “Wacom must restore the proper functioning of its governance framework without delay. In addition to proposing the dismissal of Mr Ide and Mr Nakajima, whom AVI has concluded are central to these governance failures, AVI has also nominated a candidate for outside director capable of strengthening governance and management. We are confident that, through the board structure recommended by AVI and the implementation of operational improvement measures, Wacom can further reinforce its position as the global market leader in the graphic tablet business.” About Asset Value Investors (AVI): AVI is an investment management company established in London, United Kingdom, in 1985. AVI has invested in Japanese equities for more than 40 years. AVI manages AVI Global Trust (AGT) and AVI Japan Opportunity Trust (AJOT) and other funds, collectively investing Y180bn into the Japanese market. AGT and AJOT are public companies whose shares are listed and traded on the main market of the London Stock Exchange. AVI is a signatory to Japan’s Stewardship Code and is committed to constructive engagement with management teams and boards of its portfolio companies, with the aim of contributing to sustainable growth and enhanced enterprise value. AVI’s holding in Wacom on behalf of all its funds is 13.8% making AVI the largest shareholder (as of 30 April 2026). Wacom is a 5.5% holding in AJOT. Media Contacts: KL Communications, AVI@kl-communications.com +44 (0)20 3882 6644 Ashton Consulting, avijapanpr@ashton.jp This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com. RNS Reach: https://www.londonstockexchange.com/news-article/AJOT/avi-urges-the-dismissal-of-two-directors-at-wacom/17592170
More
Galaxy Payroll Group Limited Reports Improved Interim Results and Positive Operating Cash Flow ACN Newswire

Galaxy Payroll Group Limited Reports Improved Interim Results and Positive Operating Cash Flow

HONG KONG, May 14, 2026 - (ACN Newswire via SeaPRwire.com) - Galaxy Payroll Group Limited (NASDAQ: GLXG) (“GLXG” or the “Company”), a provider of payroll outsourcing and employment services, today announced its unaudited financial results for the six months ended December 31, 2025.Financial Highlights· Revenue increased to HKD14.0 million (US$2.0 million), representing year-over-year growth of approximately 2%· Total number of customers increased from 196 to 210· Net loss improved significantly from HKD26.5 million (US$3.4 million) to HKD1.1 million (US$0.1 million)· Operating expenses declined substantially following normalization of prior-period non-recurring expenses· Net cash provided by operating activities was HKD1.25 million (US$0.2 million)· Cash balance increased to HKD33.2 million (US$4 million) as of December 31, 2025The Company’s employment services business continued to expand across multiple Asian markets, supported by growing demand for cross-border employment and outsourcing solutions.The substantial reduction in net loss compared to the prior period primarily reflected the absence of certain one-time research and development expenditures and listing-related costs incurred during the prior fiscal year.For the full interim unaudited financial statements for the six months ended December 31, 2025, please refer to the report of foreign issuers furnished by the Company with the United States Securities and Exchange Commission on the even day of this release.Business UpdateThe Company has also observed encouraging business activity entering 2026, including increases in client headcount across selected accounts and continued onboarding of projects in multiple markets. These observations are preliminary in nature and may not necessarily be indicative of future financial results.Capital PositionAs of December 31, 2025, the Company maintained cash and cash equivalents of approximately HKD33.2 million (US$4 million) and positive working capital. Management believes the Company’s current liquidity position supports its present operating plan and ongoing business development activities.Based on current expectations, the Company does not currently expect to require near-term external equity financing and has no present intention to establish an at-the-market (“ATM”) offering program over the next 12 months. This assessment remains subject to market conditions, business performance, and strategic considerations.Management CommentaryWai Hong Lao, Chief Executive Officer of GLXG, commented:“Our interim results reflect continued progress in stabilizing and strengthening our operating profile following our public listing. While revenue growth remained modest during the period, we achieved meaningful improvement in our cost structure and operating performance.We are encouraged by the continued expansion of our customer base, positive operating cash flow, and ongoing business activity entering 2026. We remain focused on disciplined execution, prudent capital management, and building long-term shareholder value.”About Galaxy Payroll Group LimitedGalaxy Payroll Group Limited is a provider of payroll outsourcing and employment services operating across multiple Asian markets.Forward-Looking StatementsThis press release contains forward-looking statements within the meaning of applicable securities laws. These statements are based on current expectations and assumptions and are subject to risks and uncertainties that could cause actual results to differ materially. Factors that could cause such differences include, but are not limited to, market conditions, customer demand, competitive conditions, regulatory developments, financing conditions, and the Company’s ability to execute its business strategy. Forward-looking statements include statements regarding future business activity, growth expectations, liquidity, and financing intentions. The Company undertakes no obligation to update forward-looking statements except as required by law. Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com
More
金山科技签订6.75亿绿色及可持续发展表现挂钩贷款 ACN Newswire

金山科技签订6.75亿绿色及可持续发展表现挂钩贷款

香港, 2026年5月14日 - (亚太商讯 via SeaPRwire.com) - 2026年5月11日,金山科技工业有限公司("金山科技",00040.HK)签订一项 6.75 亿港元绿色及可持续发展表现挂钩贷款("GSLL 银团贷款")。此银团贷款由十家主要银行提供:恒生银行有限公司担任独家委任牵头安排行兼簿记行,牵头行为上海商业银行有限公司,共同安排行为马来亚银行,其他安排行包括彰化商业银行股份有限公司-香港分行、东莞银行(国际)有限公司、浙商银行股份有限公司(香港分行)、合作金库商业银行股份有限公司-香港分行、台湾新光商业银行股份有限公司-香港分行、第一商业银行股份有限公司-澳门分行及华南商业银行股份有限公司-国际金融业务分行。尽管全球环境充满挑战,此项6.75亿港元的GSLL银团贷款仍彰显银行业界对金山科技在落实与推进环境、社会及管治("ESG")方面所展现的承诺及良好往绩,持有坚定信心并给予有力支持。金山科技主席兼总裁罗仲荣表示:"金山科技致力投入长远可持续发展,并已取得相当成效。这项 GSLL 银团贷款不仅是对我们策略方向的肯定,亦加强了我们追求创新融资方案和运营方式的能力,以支持可持续的业务增长。"金山科技副主席兼执行副总裁李耀祥表示:"作为电池、音响及电子业的领先企业,金山科技致力将永续理念全面融入各个营运层面。 我们在推动落实永续策略上已取得稳健且可量化的进展,充分展现对履行企业公民责任的承诺,以及对创造长期价值的坚定决心。""我们提倡使用充电池,以减少浪费资源。GP Recyko 充电池系列已广受市场接受,而我们亦持续提升充电效率,让电池可在短短一小时内完成充电,进一步鼓励消费者改变习惯,由一次性电池转用充电池。""我们持推动环保包装:现时欧洲超过 1,000 种 GP 品牌消费类电池产品,已由纸料代替塑胶包装。 据此,我们成功录得 48 吨塑胶及 30 吨材料废弃物的年减幅。"GP 能源科技 ─ 集团的可持续能源方案业务 ─ 在本年一月达成重要里程碑,在中国东莞启用首座镍锌电池制造工厂,此举亦象征金山科技朝新一代镍锌电池解决方案的发展迈出重要一步,以镍锌高功率密度、高度可回收性及不易燃等特性,大大提升即时电源的表现。镍锌电池为数据中心及其他重要基础设施的不间断电源系统(Uninterruptible Power Supply, UPS)提供可靠且永续的供电方案。 GSLL 银团贷款将支持集团进一步推展镍锌电池业务,迈向更安全且永续的未来。金山科技将永续视为推动盈利与长期增长的重要因素。于2024/25年度,集团在范畴一及范畴二温室气体排放量相较 2023/24年度的减幅达 4%。集团将持续致力达成中期与长期减量目标,重点如下:• 于 2030 年或以前,相比 2023/24 年度的基准减少 20%;• 于 2040 年或以前,减少 60%;• 于 2050 年或以前,实现净零营运碳排放(即减少 100%)。金山科技致力环保减废,取得多项相关殊荣及认证,当中集团六间电池制造设施获得UL Solutions"废弃物零填埋"铂金或金级认证,显示其透过有效减少废物和分流策略,成功减少95-100%的堆填废弃物。 此外,金山电池及GP能源科技于2025/26年度同时取得EcoVadis铜牌。 集团亦持续加强工厂的太阳能装置,落实减碳目标。恒生银行商业银行业务总监李秀怡表示:"此项银团融资安排反映市场对金山科技长远发展策略及可持续发展工作的信心。 恒生银行很荣幸担任本次交易的独家委任牵头安排行兼簿记行,提供以明确的可持续发展目标为导向、并激励达标表现的融资结构,同时支持集团持续投资于充电池制造业务。 作为长期合作伙伴,我们期待与金山科技紧密协作,推动融资与可持续发展的融合,为社区及持份者创造长远价值。"这项为期三年的 GSLL 绿色银团贷款设有分级奖励机制,金山科技每达到既定的 GSLL 银团贷款可持续发展目标时可享受利息减免。 集团计划将是次贷款所得款项用于强化财务状况、加速充电池及可持续能源方案业务发展、支持用于先进制造技术的长期投资、提升运营效率,并加强其对可持续商业实践的承诺。(中) 金山科技副主席兼执行副总裁李耀祥与十间主要银行签订6.75亿GSLL银团贷款(左七) 金山科技主席兼总裁罗仲荣感谢银行界支持促成是次 GSLL 银团贷款金山科技集团黄思珞 高级企业传讯经理电话:(852) 2485 5328电邮: charlotte_wong@goldpeak.comAJA Capital 艾明资本庾婉华 / 吕婉琪电话:( 852) 9500 4443 / 9155 5615电邮:avy.yu@ajacapital.com.hk / janet.louie@ajacapital.com.hk金山科技集团简介金山科技集团为一家电池及电子跨国企业,锐意成为提供电能及音响方案的领导者之一,并以可持续原则为发展重点,令人类生活更充实,更有动力。集团母公司金山科技工业有限公司[0040.HK]于1964年成立,并自1984年在香港上市。 金山科技现时拥有GP工业有限公司 86.18%*股权,作为其主要投资工具。GP工业在新加坡上市。金山科技直接持有 GP 能源科技国际有限公司,主力研发创新充电池技术及开发环保储能电池方案企业对企业(B2B)电池业务。GP工业则专注发展消费类电池、电子产品及扬声器业务。集团之主要产品类别如"GP超霸"电池、"GP 绿再"充电池、"KEF"高级扬声器和"Celestion"专业扬声器,已成为业内著名品牌。 金山科技集团之生产设施、产品研究发展及销售办事处遍布全球十多个国家。www.goldpeak.com(* 于 2026 年 5 月 11 日持有之股权) Copyright 2026 亚太商讯 via SeaPRwire.com. All rights reserved. www.acnnewswire.com
More
Euro Manganese Announces Positive Preliminary Economic Assessment ACN Newswire

Euro Manganese Announces Positive Preliminary Economic Assessment

Vancouver, British Columbia--(ACN Newswire via SeaPRwire.com - May 14, 2026) - Euro Manganese Inc. (TSXV: EMN) (ASX: EMN) (FSE: E060) and its subsidiary Mangan Chvaletice, s.r.o. ("Mangan" and together the "Company", "Euro Manganese" or "EMN") is pleased to announce the results of a new Preliminary Economic Assessment ("PEA") for the development of its Chvaletice Manganese Project ("Chvaletice Manganese Project", "CMP", or "Project") in the Czech Republic.The PEA is a result of the Company's Optimization Program previously announced1, and builds on the extensive knowledge presented in the Company's Technical Report and Feasibility Study for the Chvaletice Manganese Project, Czech Republic, dated effective July 27, 2022[2], (the "2022 Feasibility Study"). The PEA responds to current market conditions and incorporates the Company's testing campaigns, demonstration plant learnings, and prospective customer testing and feedback to provide an updated preliminary and conceptual development path for the Chvaletice Manganese Project.With most permits secured, a finalized Environmental Impact Assessment ("ESIA"), and official designation as a Strategic Deposit under Czech law and a Strategic Project under the EU Critical Raw Materials Act, Euro Manganese is ready to respond to customers seeking a fully traceable battery-grade manganese supply chain, reducing dependence on Chinese sources and supporting strategic mineral independence objectives.The Chvaletice Manganese Project is well placed to take advantage of U.S. federal procurement and incentive frameworks that increasingly require that critical battery materials — including high-purity manganese used in electric vehicle and energy storage applications — be sourced from allied and US National Defense Act ("NDAA") compliant nations. The Czech Republic, as a NATO member and close U.S. ally, qualifies as an NDAA-compliant source country.HIGHLIGHTS(All economic values are in US dollars unless indicated otherwise)Strong Operating Margin of 48%, demonstrating resilience of the Project and the potential to generate significant returns across commodity price cycles.Robust Returns: Pre-tax IRR of 16.0% and Post-tax IRR of 13.8%, underpinned by a pre-tax NPV of $740M and post-tax NPV of $492M (8% discount rate), showing favorable preliminary economic indicators on historically conservative pricing assumptions.Higher Recoveries, 60% for High-Purity Manganese Sulphate Monohydrate (HPMSM) and 61% for High Purity Manganese Metal (HPEMM), reflecting additional metallurgical test work, operational learnings from the demonstration plant, and process engineering updates.Revised Flowsheet supports 50,000 tpa of HPEMM with full conversion to 150,000 tpa of HPMSM, aligning with battery industry demand while maintaining flexibility to deliver both HPEMM and HPMSM products as customer needs evolve.Newly incorporated magnesium carbonate ("MgCO3") resource as a by-product enables production of up to 20,000 tpa MgCO3, adding incremental value with minimal capital.CAPEX costs remain broadly consistent with the 2022 Feasibility Study, including with increased HPMSM output, despite an inflationary environment.OPEX reduced for per unit cost of HPMSM compared to the 2022 Feasibility Study, due to increased production of HPMSM and updated reagents and energy costs.Updated pricing assumptions demonstrates potential economic viability of the Project even under conservative current market conditions, underscoring its durability through price cycles.Phased development reduces upfront capital requirements, lowers funding risk, and allows further optimization before full-scale expansion.Phase II buildout planned shortly after Phase I commissioning to maximize project value and shareholder returns.Initial Capital, Phase One (50% capacity): $627.5M; Plant Capacity Expansion Capital, Phase Two (to 100% capacity): $197.8M.Annual nominal production: 150,000 tpa HPMSM.Project life: 26 years.Average life of project HPMSM price assumed at $2,888 per tonne.NEXT STEPSThe PEA has enabled the Company to optimize inputs based on current pricing, establishing the possibility for a two-stage construction strategy. This phased approach has the potential to allow for further optimization in phase two, lower upfront capital requirements, and enhance project economics by aligning investment with cash flow.The Company will now advance the Chvaletice Manganese Project further towards a full feasibility study, with a targeted completion in H1 2027.The Company will also continue to monitor high purity manganese markets and strategic sectors to which it contributes, including energy transition, grid-scale energy storage, e-mobility and aerospace and defence technologies.The Company will continue to engage with potential customers to secure additional offtake term sheets, pursue offtake agreements, and continue product testing.In addition, during 2026, the Company is focused on the following key priorities to position the Project for its next development phase by:Advancing the financing strategy by securing funding for Project priorities and progressing strategic financing discussions with potential partners;Completing the acquisition of, or access to, the remaining land surface rights required for full Project development;Strengthening the Project's regulatory foundation through the continuous advancement of permitting, further reducing development risk and demonstrating Project readiness; andMaximizing non-dilutive capital by actively pursuing grants and incentives available from the EU and the Czech state.Martina Blahova, President & CEO of Euro Manganese, commented:"The publication of these PEA results marks another important milestone for the Chvaletice Manganese Project. Our recent optimization work has delivered measurable improvements in recovery, confirming both the strength of our technical strategy and the reliability of our process. To enhance capital efficiency and align investment with market demand, we have adopted a phased construction approach that maximizes value while reducing execution risk. The addition of by-product revenue stream further incrementally strengthens the economics of the project."This disciplined approach, coupled with conservative product pricing assumptions, supports a robust project profile with a strong operating margin of 48%, underscoring the Project's ability to perform through market cycles. Despite the challenging market and pricing conditions, the PEA results demonstrate the strength and resilience of the Project. It provides a clear pathway to unlocking the full long-term value of the Chvaletice Manganese Project as demand accelerates for localized, traceable, and sustainably produced battery grade high purity manganese. We are built to perform in volatile markets, engineered for operational efficiency, and positioned to play a strategic role in securing resource independence and reducing vulnerability amid an increasingly complex global landscape."Rick Anthon, Chairman of Euro Manganese, commented:"As a Board, we are encouraged by the progress reflected in this PEA and confident the Chvaletice Manganese Project can deliver on these terms for its shareholders, customers and stakeholders. The team has advanced the Project with a clear focus on technical rigour, capital efficiency, and responsible development. The phased construction strategy and strengthened economic profile demonstrate a thoughtful approach to building a long-life asset that can scale with market demand."With no operating manganese mines in Europe and as the only integrated high purity manganese producer in Europe and North America, the Chvaletice Manganese Project is uniquely positioned to become a cornerstone of Europe's emerging battery materials supply chain. The Project's strategic relevance, combined with its strong environmental credentials and growing commercial traction, reinforces our confidence in its long-term value. We believe the foundations are now firmly in place for Chvaletice Manganese Project to move toward the next stage of development and deliver meaningful returns for shareholders."PEA SUMMARY AND ECONOMIC ANALYSISThe PEA was completed by Tetra Tech Canada Inc. ("Tetra Tech"). A NI 43-101 technical report on the PEA will be filed under the Company's profile on SEDAR+ within 45 days of this news release and made available on the Company's website. A JORC report will be lodged with the Australian Securities Exchange ("ASX") ASX shortly thereafter.The following summarizes the material assumptions used in, and the results of, the PEA, assuming a targeted start of production in 2032.The Czech corporate income tax rate is 21%. In addition to the royalty of CZK 2,308 per tonne of unit Mn produced, the Czech Republic has various payroll and other taxes to generate revenue.The Company has modeled the economics of this project conservatively from a tax perspective, with a full tax burden, based on Czech legislated tax rates.Investment incentives exist in the Czech Republic and the European Union for certain, qualified investments, including investment tax credits, grants, and accelerated depreciation.The Company is actively pursuing these non-dilutive funding opportunities, including investment tax credits, grants, and accelerated depreciation available under both Czech and EU frameworks.Sensitivity AnalysisA sensitivity analysis for the Chvaletice Manganese Project was carried out to determine the effects of key variables in relation to the post-tax NPV of $492 million at a real discount rate of 8%. The results of the sensitivity analysis are presented in Table 3 below.Initial and Sustaining Capital EstimatesCapital expenditure estimates have been prepared for both initial and sustaining capital. A projected summary timeline of scheduled capital costs is shown in Table 4.The expected initial capital expenditures (Table 4) for the Project, inclusive of capitalized operating startup costs, as estimated by Tetra Tech, as of Q1, 2026, are $627.5 million, including all development-related costs that will be incurred prior to the envisaged commencement of commercial operations. Capital costs incurred after startup are assigned to sustaining capital and are projected to be paid out of operating cash-flows (also see Table 5). Contingencies on initial capital expenditure have been added at appropriate percentages to each component of the Project, excluding capitalized operating costs, resulting in an overall contingency of $66.7 million or 15.5% of direct costs.The Project site is served by excellent existing infrastructure, including rail, highway, a gas pipeline, and water and is adjacent to an operating power plant. The proposed plant site is zoned for industrial use and is the site of the former process plant that produced the Chvaletice tailings.New and refurbished infrastructure that will be built to service the Project include a tailings excavation and handling facility: a south and north site connection utility bridge for transporting tailings slurry, return water pipes and the tube conveyor that returns a mixture of non-magnetic tailings and washed leach residue to the residue dry stacking area; a magnetic separation beneficiation plant; enclosed and winterized process plant buildings and various reagent storage facilities and product warehouse; an upgraded rail spur system with related loading/unloading facilities; an internal road network; an incoming electrical 400kV high voltage grid connection including rectifiers, transformers, GIS switchgear, and local distribution step-down transformers; a process equipment maintenance workshop; a mobile fleet maintenance workshop; spare part and maintenance supply warehouses; a comprehensive water management system, onsite laboratories; and general administrative offices.Operating Cost EstimateOnsite operating costs are expected to average $181.99 per tonne plant feed ($4.14 per kg Mn equivalent) with offsite operating costs estimated to average $31.73 per tonne plant feed ($0.72 per kg Mn equivalent), as shown in Table 5.Resource EstimateTetra Tech was engaged to oversee the planning and execution of sampling and assaying, to prepare the updated Resource Estimate for EMN's Chvaletice Manganese Project, to prepare the Technical Report in accordance with National Instrument 43-101 - Standards and Disclosures for Mineral Projects, and to prepare the independent JORC Code technical report in accordance with the Joint Ore Reserves Committee Australasian Code for Reporting of Exploration Results, Mineral Resources and Ore Reserves 2012 Edition ("JORC Code"). The 43-101 Technical Report, entitled "Technical Report and Mineral Resource Estimate for the Chvaletice Manganese Project, Chvaletice, Czech Republic", with an effective date of December 8, 2018 ("the Mineral Resource Estimate"), was filed on SEDAR on January 28, 2019. The corresponding JORC Code technical report with an effective date of December 8, 2018, was lodged on the ASX on February 6, 2019.No additional drilling or data collection pertaining to the technical disclosure of mineral inventory has been undertaken since the completion of the Mineral Resource Estimate, and the effective date for Mineral Resource Estimate is revised to April 27, 2026.The Project's combined Measured and Indicated Resources now amount to 26,960,000 tonnes, grading 7.33% total manganese (tMn) and 5.86% soluble manganese (sMn), as detailed in Table 6 below.PROCESSING FACILITIES DESCRIPTIONTailings Extraction, Residue Storage Facility and ReclamationIn the tailings extraction plan, the three tailings cells will be excavated in a counterclockwise sequence, starting with Cell #3, followed by Cells #1 and #2. Tailings will be extracted using shovel excavators and hauled by truck to an intermediate re-pulping and a covered storage station located between Cells #1 and #2. The storage station will create a 5-day material stockpile. Re-pulped tailings will be fed to the magnetic separation plant via a slurry pipeline on a continuous basis.A filtered blend of non-magnetic tailings and washed leach residue materials from the process plant will be conveyed using a tube conveyor to the storage station and placed and compacted in the Residue Storage Facility (RSF). The excavated area exposed after extraction of the existing tailings will be lined with a geomembrane liner. The RSF will be constructed in stages to suit residue storage requirements and progressively covered to limit the footprint of residue exposed to the air at any given time.RSF design features include a geomembrane lined bottom, perimeter surface water diversion and a contact water collection system that is integrated with the overall site water management system. Dust management includes the implementation of modern dust suppression methods on open faces, interim stack surfaces and haul roads, as required.Progressive reclamation will be undertaken as an integrated part of the residue stacking procedure. The filtered residue cover will consist of a low permeability soil and/or geomembrane cover to inhibit erosion and infiltration, and a growth layer to support vegetation growth.The site is expected to be fully reclaimed and brought back into a productive community to be established in consultation with local communities, regulators and national government agencies. The RSF will be monitored during the post-closure period for geotechnical and environmental performance.High Purity Manganese Products Production FacilityThe processing facilities, including ancillary facilities, for HPMSM production from the CMP tailings were designed by Beijing General Research Institute for Mining ("BGRIMM") together with EMN and Tetra Tech, based on the comprehensive metallurgical test results conducted during the previous PEA and validated through bench scale tests during the feasibility study. Additional metallurgical tests to recover manganese from anode slimes from electrowinning circuit were also conducted to support this PEA.The study was based on the design work completed for the 2022 Feasibility Study which included process circuit and process equipment optimization. Key equipment items were sized and selected based on the FS design by upgrading HPMSM circuit from the nominal capacity of 100,000 t/a to 150,000 t/a. In addition, two additional circuits, one for manganese recovery from anode slimes produced from the electrowinning circuit using reductive leaching and one for sodium and potassium removal from the HPMSM crystallization circuit by incorporating a high-temperature crystallization bypass system. One additional circuit to convert the magnesium carbonate from waste to a saleable by-product is incorporated into the magnesium removal circuit.The CMP process plant has been designed for a nominal nameplate production capacity of 150,000 tonnes per annum of HPMSM by processing approximately 1.1 million tonnes of the historical tailings per year.HPMSM is produced by converting HPEMM flakes produced by electrowinning process without the use of selenium and chromium. This product is expected to best meet the high purity manganese market demand anticipated in current and future battery formulations.The CMP HPMSM product is designed to contain no less than 99.9% high purity manganese sulfate monohydrate and a minimum of 32.34% manganese and will be sold in powder form, produced without the use of fluorine.The dried HPMSM powder product will be packed prior to being shipped in trucks or containers to customers .The process includes following unit circuits:High-intensity wet magnetic separation circuit, upgrading the excavated tailings manganese grade to approximately 15% tMn for acid leaching.Magnetic concentrate sulfuric acid leaching, neutralization to remove impurities and solid-liquid separation.Pregnant leach solution deep purification to further remove heavy metals.Manganese electrowinning to produce high purity HPEMM (high-purity electrolytic manganese metal) flakes using a selenium free process.A magnesium removal process circuit to ensure efficient electrowinning operations and high-quality product and magnesium carbonate produced as a by-product.HPEMM dissolution, solution purification and HPMSM crystallization and drying to produce battery-grade HPMSM for sale.Other supporting circuits, such as ammonium recovery system, water management systems, steam generation. The proposed process flow sheet is illustrated in Figure 1 below.Figure 1: Updated Simplified Process FlowsheetTo view an enhanced version of this graphic, please visit:https://images.newsfilecorp.com/files/11453/297390_4c2a5f3814e549ad_001full.jpgENVIRONMENTAL IMPACTS, PERMITTING AND COMMUNITY ENGAGEMENTEnvironmental impacts are monitored over the long term as part of the project. The ESIA process was conducted in two phases, supplemented by several expert studies and on-site monitoring. The result of the ESIA process, which involved participation from relevant authorities and the public, is the positive Environmental and Social Binding Statement, which was issued by the Ministry of Environment in March 2024. The ESIA permit is a crucial permit demonstrating that the assessed impacts on individual environmental components and the social sphere are acceptable and that the project is feasible.The assessment results show that the implementation of the project will not worsen existing environmental conditions and will not have negative social impacts. Furthermore, the realization of the project will reduce the identified contamination of groundwater and surface water in the tailings and its vicinity, where the source of the pollution is demonstrably deposited material. As the deposit is of anthropogenic origin and the mined material is a waste-product, this constitutes the reuse or recycling of waste, aligning with the principles of the circular economy. The aim of remediation and reclamation is to create a near-natural area with high biodiversity and stability, which will be used for recreational and sports activities.The ESIA process is followed by a subsequent permitting process when a significant portion of the permits had already been obtained, such as the Permit for the location of the processing plant, the Permit for the location of the rail spur, Product registration under the EU's REACH Regulation, and other permits related to auxiliary activities (utility relocations, grid connection, and others). Another key permit is the Determination of the Mining Lease Permit, which was granted to MANGAN Chvaletice, s.r.o on January 23, 2025; this is another crucial permit which authorizes the company to conduct mining activities. In the following steps, the company will undergo the permitting process stipulated by the Building Act, followed by the final operating permit.In 2026, the Company will continue to advance the permitting process under the Building Act, targeting completion of the final operating permit pathway in line with the feasibility study timeline. Each permitting milestone achieved further reduces Project risk and reinforces the Company's readiness to move into the next phase of development.Key Highlights of the Social Commitment:Significant Economic Catalyst: The Project will act as a primary economic driver in the Pardubice Region, creating 800-1,000 jobs during construction and providing stable, long-term employment for approximately 400 direct staff during operations, with a strong 85% local hiring commitment.Commitment to Transparency: The Project has established a robust engagement framework, including a dedicated public information center in Chvaletice and dedicated digital platforms (project-specific website and online grievance tools).Validated Social Acceptance: On March 27, 2024, the Czech Ministry of the Environment issued a favorable binding ESIA opinion, confirming that the Project meets the highest environmental and social standards. The Project currently faces no material barriers to acceptance, reflecting a strong Social License to Operate.BENEFITS OF PEA AND NEXT STEPSThe PEA enabled the Company to optimize inputs based on current pricing, establishing the possibility for a two-stage construction strategy. This phased approach has the potential to allow for further optimization in phase two, lower upfront capital requirements, and enhance project economics by aligning investment with cash flow. The Company plans to explore this and other avenues to advance the Chvaletice Manganese Project further towards feasibility study, with targeted completion in H1 2027.The Company will also continue to monitor high purity manganese markets and strategic sectors to which it contributes, including energy transition, grid-scale energy storage, e-mobility and aerospace and defence technologies. The Company will continue to engage with potential customers to secure additional offtake term sheets, pursue offtake agreements, and continue product testing.In addition, during 2026, the Company is focused on the following key priorities to position the Project for its next development phase by:Advancing the financing strategy by securing funding for Project priorities and progressing strategic financing discussions with potential partners;Completing the acquisition of, or access to, the remaining land surface rights required for full Project development;Strengthening the Project's regulatory foundation through the continuous advancement of permitting, further reducing development risk and demonstrating Project readiness; andMaximizing non-dilutive capital by actively pursuing grants and incentives available from the EU and the Czech state.Competent and Qualified Person StatementAll production targets for the Chvaletice Manganese Project referred to in this news release are underpinned by estimated Measured and Indicated Mineral Resources prepared by Competent Persons and Qualified Persons in accordance with the requirements of the JORC Code and NI 43 - 101, respectively. Additionally, the scientific and technical information included in this news release, is based upon information prepared, verified, and approved by Mr. James Barr, P. Geo, Senior Geologist, Mr. Jianhui (John) Huang, Ph.D., P. Eng., Senior Metallurgical Engineer, Mr. Hassan Ghaffari, P.Eng, M.A.Sc., Senior Process Engineer, Mr. Chris Johns, P.Eng, Senior Geotechnical Engineer, and Mrs. Maurie Marks, P.Eng, Senior Mining Engineer, all with Tetra Tech. Mr. Barr, Mrs. Marks, Mr. Ghaffari, Mr. Johns, Mr. Hasanloo and Mr. Huang are consultants to, and independent of, EMN within the meaning of NI 43-101, and have sufficient experience in the field of activity being reported to qualify as Competent Persons as defined in the JORC Code, and are Qualified Persons, as defined in NI 43-101. Mr. Barr is responsible for the Mineral Resource Estimate, Mr. Huang is responsible for the metallurgical test work results, process engineering, operating cost and capital cost estimates, environmental studies, permitting, and social or community impact. Mr. Ghaffari is responsible for infrastructure, Mrs. Marks is responsible for mining and financial analysis, Mr. Johns is responsible for design of the residue storage facility. Mr. Barr visited the property during the 2017 drilling program and again during the 2018 drilling campaign, on July 30-31st, 2018, during which time he observed the drilling, sample collection and preparation, sample logging and sample storage facilities. Mr. Huang visited the Project site on February 5, 2018 and May 3, 2022, as well as visited the Changsha Research Institute of Mining and Metallurgy Co. ("CRIMM") laboratory and pilot plant facility five times between January 20, 2017 and September 20, 2018 to witness sample preparation and test/assay facilities and to discuss the test program and results with CRIMM's technical team. Mr. Huang also visited the SGS Minerals Services (SGS) laboratory on June 29, 2017, and oversaw the bench scale validation test work completed by BGRIMM. Mrs. Marks, Mr. Johns and Mr. Ghaffari also visited the project site on May 3, 2022. Barr, Huang, Ghaffari, Johns and Marks have no economic or financial interest in the Company and consent to the inclusion in this news release of the matters based on their information in the form and context in which it appears.In addition, technical information concerning the Chvaletice Manganese Project is reviewed by Dr. David Dreisinger, P. Eng, a Qualified Person under NI 43-101. Dr. Dreisinger has reviewed and approved the information in this news release for which he is responsible and has consented to the inclusion of the matters in this news release based on the information in the form and context in which it appears.Cautionary StatementThe PEA is a high-level review of potential, is preliminary in nature, and there is no certainty that the economics in the PEA will be realized. The PEA results are not equivalent to, and should not be construed as, a Pre-Feasibility Study or Feasibility Study. Accordingly, investors are reminded that the PEA is considered preliminary in nature and includes estimated costs that are subject to an approximate margin error of plus or minus 35%. Mineral Resources that are not Mineral Reserves do not have demonstrated economic viability, and there is no guarantee the Project's resources will eventually be classified as reserves.The projected process plant design, potential production profile and project plan are conceptual in nature and additional technical studies will need to be completed in order to fully assess their viability. There is no certainty that a potential production decision will be made, or that a commercial operation will be achieved.A sensitivity analysis for the Project was carried out to determine the effects of key variables in relation to the post-tax NPV of US$492 million using a real discount rate of 8%. The results of the sensitivity analysis are presented in Table 3 of this announcement. Additional sensitivities from changes in capital and operating costs, recoveries, and metal prices are also included in Table 3.The PEA is also based on the material assumptions outlined in this announcement. These include assumptions about the availability of funding. While EMN considers all of the material assumptions to be based on reasonable grounds, including those related to funding, there is no certainty that they will prove to be correct or that the range of outcomes indicated by the PEA can be achieved.To achieve the range of outcomes indicated in the PEA, funding in the order of approximately US$670.9 million is assumed to be required for initial capital expenditures and working capital. It is anticipated that funding will be sourced through a combination of equity and debt, and possibly other means; however, given that the PEA is considered preliminary in nature, the Company expects to finalize its financing strategy for the Project in conjunction with, or after, the completion of the feasibility study.Investors should note that there is no certainty that EMN will be able to raise that amount of funding when needed. It is also likely that such funding may only be available on terms that may be dilutive to or otherwise affect the fundamental value of EMN's existing shares. It is also possible that the Company could pursue other 'value realisation' strategies such as a sale, partial sale or joint venture of the Project. If such strategies are pursued, it could materially reduce EMN's proportionate ownership of the Project. Given the uncertainties involved, investors should not make any investment decisions based solely on the results of the PEA.Euro Manganese is dual listed on the TSX-V and the ASX. Neither TSX Venture Exchange nor its Regulation Services Provider (as defined by TSXV policies) or the ASX accepts responsibility for the adequacy or accuracy of this release.Authorized for release by the President and CEO of Euro Manganese Inc.Martina BlahovaPresident and CEO+1 (604) 681-1010info@mn25.caJane Morgan ManagementJane MorganInvestor and Media Relations - Australia+61 (0) 405 555 618jm@janemorganmanagement.com.auLodeRock AdvisorsNeil WeberInvestor and Media Relations - North America+1 (647) 222-0574neil.weber@loderockadvisors.com About Euro ManganeseEuro Manganese Inc. (TSXV: EMN) (ASX: EMN) (FSE: E060) is a battery materials company developing the Chvaletice Manganese Project in the Czech Republic, Europe's only near-term source of high-purity manganese, a critical ingredient in next-generation electric vehicles, energy storage batteries and defence applications.The Chvaletice Manganese Project aims to reprocess historic mine tailings to produce high-purity electrolytic manganese metal (HPEMM), and high-purity manganese sulphate monohydrate (HPMSM), establishing a fully traceable, low-carbon supply chain within the European Union.Euro Manganese is positioned to become Europe's first domestic producer of high-purity manganese, meeting the rising demand for sustainable, strategic battery materials while advancing Europe's clean-energy and supply-chain independence goals.Forward-Looking StatementsCertain statements in this news release constitute "forward-looking statements" or "forward-looking information" within the meaning of applicable securities laws. Such statements and information involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance, or achievements of the Company, its Chvaletice Project, or industry results, to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements or information. Such statements can be identified by the use of words such as "may", "would", "could", "will", "intend", "expect", "believe", "plan", "anticipate", "estimate", "scheduled", "forecast", "predict" and other similar terminology, or state that certain actions, events or results "may", "could", "would", "might" or "will" be taken, occur or be achieved.Readers are cautioned not to place undue reliance on forward-looking information or statements. Forward-looking statements are subject to a number of risks and uncertainties that may cause the actual results of the Company to differ materially from those discussed in the forward-looking statements and, even if such actual results are realized or substantially realized, there can be no assurance that they will have the expected consequences to, or effects on, the Company.Forward looking information or statements include all of the results of the PEA, including estimates of internal rates of return (including any pre-tax and after-tax internal rates of return, payback periods, net present values, future production, estimates of cash cost, assumed prices for HPEMM and HPMSM and by-products, proposed extraction plans and methods, operating life estimates, cash flow forecasts, metal recoveries and estimates of capital and operating costs. Forward looking statements also include the possibility for a two-stage construction strategy, and the potential to allow for further optimization of the Project in phase two, with lower upfront capital requirements, and to enhance project economics by aligning investment with cash flow. The Company has based its assumptions and analysis on certain factors that are inherently uncertain, including (i) the adequacy of infrastructure; (ii) the ability to develop adequate processing capacity; (iii) the price of HPEMM and HPMSM and by-products; (iv) the availability of equipment and facilities necessary to complete development; (v) the size of future processing plants and future tailings extraction rates; (vi) the cost of consumables and extraction and processing equipment; (vii) unforeseen technological and engineering problems; (viii) currency fluctuations; (ix) changes in laws or regulations; (x) the availability and productivity of skilled labour; and (xi) the regulation of the mining industry by various governmental agencies.Forward-looking statements also include statements regarding the Company's strategy for its Chvaletice Project, ability to access high purity manganese markets and strategic sectors to which it contributes, including energy transition, grid-scale energy storage, e-mobility and aerospace and defence technologies and sell its products, the ability to complete a feasibility study in 2027, and the Company's ability to navigate current market conditions. In addition, forward-looking statements include statements regarding the Company's next steps including: advancing financing efforts; seeking strategic partners, finalizing product testing, and negotiating offtake agreements with customers; Securing remaining land access; progressing key permits; and pursuing government funding.All forward-looking statements are made based on the Company's current beliefs including various assumptions made by the Company, including that the Chvaletice Project will be developed and operate as planned, the results of the PEA are reliable, that the Company will have sufficient financing to continue operations, and that the Company will be able to meet the conditions of its secured financing. Factors that could cause actual results or events to differ materially from current expectations include, among other things: results from the PEA are not accurate; insufficient working capital; inability to meet the conditions of its secured financing, risks due to granting security, lack of availability of financing for developing and advancing the Chvaletice Project; no available government funding or incentives; the potential for unknown or unexpected events to cause contractual conditions to not be satisfied; developments in electric vehicle battery markets and chemistries; risks related to fluctuations in currency exchange rates; and changes in laws or regulations by various governmental agencies. For a further discussion of risks relevant to the Company, see "Risk Factors" in the Company's annual information form for the year ended September 30, 2025, available on the Company's SEDAR+ profile at www.sedarplus.ca.Although the forward-looking statements contained in this news release are based upon what management of the Company believes are reasonable assumptions, the Company cannot assure investors that actual results will be consistent with these forward-looking statements. These forward-looking statements are made as of the date of this news release and are expressly qualified in their entirety by this cautionary statement. Subject to applicable securities laws, the Company does not assume any obligation to update or revise the forward-looking statements contained herein to reflect events or circumstances occurring after the date of this news release. To view the source version of this press release, please visit https://www.newsfilecorp.com/release/297390 Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com
More
Assembly 在亚太地区推出 Stagwell Search+,人工智能重塑品牌发现方式 ACN Newswire

Assembly 在亚太地区推出 Stagwell Search+,人工智能重塑品牌发现方式

香港, 2026年5月14日 - (亚太商讯 via SeaPRwire.com) - 随着搜索日益由人工智能主导并呈现“零点击”趋势,品牌需要制定新策略,以塑造其在搜索结果中的呈现方式,而不仅仅是链接展示。亚太地区已成为全球人工智能搜索应用的领导者,78%的用户表示每周都会使用该功能。在用户访问网站之前,人工智能搜索体验正日益影响着品牌的发现与考量。为此,全球全渠道媒体代理机构Assembly今日宣布在亚太地区推出Stagwell Search+——这一全新系统旨在帮助品牌理解并影响其在AI驱动的搜索环境中的呈现方式。此次发布标志着搜索营销已从单纯的独立渠道转变为生态系统的一部分。Stagwell Search+覆盖付费、自有、 earned( earned media 指通过优质内容自然获得的媒体曝光)及共享媒体的完整生态系统,在该生态中,AI生成的答案决定了品牌的可见度与表现。这一转变在亚太地区尤为复杂。该地区的大型语言模型格局分散,涉及多种语言和文化背景,导致品牌可见性不一致。一个品牌在某个模型中可能显得权威,但在另一个模型中却可能隐形或被误解,这给营销人员带来了新的、且在很大程度上无法衡量的风险。Stagwell Search+由Assembly与emberos合作开发,搭载了业界首个面向AI搜索的代理操作系统。该平台持续监测品牌在不同模型和语言中的呈现情况,并统筹协调及衡量内容、媒体和数字渠道各项举措带来的提升效果,从而改善品牌可见度。系统并非直接将变更自动化推送至各平台,而是通过AI代理引导人类决策——帮助团队采取精准、战略性的行动,同时保障品牌体验的质量与完整性。Stagwell Search+ 目前已集成 OpenAI、Gemini、Perplexity、Grok 和 Anthropic 等全球领先的 AI 模型,并计划于今年晚些时候与 DeepSeek 等区域性平台进行进一步集成。“AI 已经在没有营销人员参与的情况下做出品牌决策——而在亚太地区,语言和文化的复杂性进一步加剧了这一挑战,”亚太区体验与激活副总裁 Yi En Chye 表示。“成功的定义不再是排名或点击量,而是品牌能否赢得‘提示词份额’。Stagwell Search+为品牌提供了在这个新环境中竞争所需的可视性和控制力。”关于 AssemblyAssembly 是一家全球全渠道代理机构,致力于为寻求更现代品牌建设方法的品牌提供服务。依托 Stagwell 网络,我们真正汇聚了数据、人才与技术,旨在自下而上(而非自上而下)释放更智能、更快速、更卓越的成果。我们充满好奇心、善于协作且勇于变革,是一支由建设者组成的团队,坚信体验越出色,表现越卓越。我们不认为品牌与绩效是二选一的关系。对我们而言,二者永远相辅相成。我们标志中的“+/”符号,即“ORAD”,正是这种思维方式的体现。它象征着我们的思维方式、构建方式以及在整个营销漏斗中交付成果的方式。Assembly 的根基建立在三个核心要素之上:专为实现目标而打造的 STAGE 体验引擎、由其驱动的战略产品——品牌绩效规划(BPP),以及为速度、深度和现代营销需求量身定制的组织架构。三者协同运作,使我们能够打造更卓越的品牌体验,重新定义品牌在数据、技术、媒体、创意和商业领域中的连接、互动与增长方式。Assembly在全球44个办事处拥有超过3,000名专家,提供全漏斗解决方案,助力全球最具雄心的品牌实现卓越表现。了解更多信息,请访问 assemblyglobal.com。关于 StagwellStagwell 是一家通过人工智能重塑营销格局的全球挑战者网络。我们为全球最具雄心的品牌提供规模化的创意营销成效,将引领文化潮流的创意与尖端技术相结合,实现营销艺术与科学的和谐统一。在企业家的领导下,我们遍布 45 多个国家的专家团队秉持共同目标:为客户提升营销效果并改善业务成果。欢迎访问 www.stagwellglobal.com 加入我们。媒体联系Kelvin Lee亚太区市场营销总监Kelvin.lee@assemblyglobal.com 来源:Assembly Copyright 2026 亚太商讯 via SeaPRwire.com. All rights reserved. www.acnnewswire.com
More
Assembly Rolls out Stagwell Search+ Across APAC as AI Reshapes Brand Discovery ACN Newswire

Assembly Rolls out Stagwell Search+ Across APAC as AI Reshapes Brand Discovery

HONG KONG, May 14, 2026 - (ACN Newswire via SeaPRwire.com) - As search becomes increasingly AI-led and zero-click, brands need new strategies to shape how they appear in answers, not just in links. APAC has emerged as a global leader in AI Search adoption, with 78% of users reporting weekly usage. Increasingly, AI Search Experiences shape brand discovery and consideration before users ever visit a website.In response, global omnichannel media agency Assembly today announced the rollout of Stagwell Search+ in APAC - a new system designed to help brands understand and influence how they are represented across AI-driven search environments.The launch marks a fundamental shift away from treating search as a standalone channel. Instead, Stagwell Search+ operates across a full ecosystem of paid, owned, earned, and shared media, where AI-generated answers determine visibility and performance. This shift is especially complex in APAC, where a fragmented landscape of large language models, spanning multiple languages and cultural contexts, creates inconsistent brand visibility. A brand may appear authoritative in one model while remaining invisible or misrepresented in another, introducing a new and largely unmeasured risk for marketers.Built by Assembly in partnership with emberos, Stagwell Search+ is powered by the industry's first agentic operating system for AI search. The platform continuously monitors how brands appear across models and languages and orchestrates & measures the lift from actions across content, media, and digital channels to improve visibility. Rather than automating changes directly into platforms, the system is designed to guide human decision-making with AI agents - helping teams take precise, strategic action while protecting the quality and integrity of brand experiences.Stagwell Search+ is currently integrated with leading global models from OpenAI, Gemini, Perplexity, Grok, and Anthropic with additional integrations across regional platforms such as DeepSeek planned for later this year."AI is already making brand decisions without marketers in the room - and in APAC, that challenge is amplified by language and cultural complexity," said Yi En Chye, VP of Experience and Activation, APAC. "Success is no longer defined by rankings or clicks, but by a brand's ability to secure share of prompt. Stagwell Search+ gives brands the visibility and control they need to compete in this new environment."ABOUT ASSEMBLYAssembly is a global omnichannel agency built for brands that want a more modern approach to building brands that perform. Backed by the Stagwell network, we are a literal assembly of data, talent, and technology built to unlock smarter, faster, and better-performing outcomes from the bottom up -not the top down. Curious, collaborative, and driven by change, we are an agency of builders who believe the better the experience, the better the performance. We don't see brand and performance as an either/or. For us, it's always both. The + symbol in our logo, known as the ORAD, represents this mindset. It's a mark of how we think, how we build, and how we deliver results across the full funnel. Assembly's foundation is built on three core elements: our purpose-built STAGE Experience Engine, the strategic product it powers-Brand Performance Planning (BPP) - and an organizational design built for speed, depth, and the demands of modern marketing. Together, they enable us to build better brand experiences that reimagine how brands connect, engage, and grow across data, tech, media, creative and commerce. With over 3,000 experts in 44 offices worldwide, Assembly delivers full-funnel solutions that help the world's most ambitious brands perform. Learn more at assemblyglobal.com.ABOUT STAGWELLStagwell is the global challenger network transforming marketing through AI. We deliver scaled creative performance for the world's most ambitious brands, connecting culture-moving creativity with leading-edge technology to harmonize the art and science of marketing. Led by entrepreneurs, our specialists in 45+ countries are unified under a single purpose: to drive effectiveness and improve business results for our clients. Join us at www.stagwellglobal.com.MEDIA CONTACTKelvin LeeMarketing Director, APACKelvin.lee@assemblyglobal.comSOURCE: Assembly Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com
More

驭势科技赴港招股:全场景L4级自动驾驶龙头 业绩稳步增长 赋能多场景自动驾驶落地

香港, 2026年5月14日 - (亚太商讯 via SeaPRwire.com) - 近年来,在政策持续护航、技术快速迭代及市场需求升级的多重驱动下,自动驾驶行业迎来黄金发展周期,持续引领产业变革与升级,成为人工智能与实体经济深度融合的核心赛道,孕育着巨大的发展机遇。5月12日,自动驾驶行业领先企业驭势科技(北京)股份有限公司("驭势科技"或"公司",股份代号:1511.HK)正式启动招股,赴港上市进程迈出关键一步,不仅标志着公司将迈入资本赋能的全新发展阶段,更将为L4级自动驾驶行业的商业化落地注入强劲动能。据悉,驭势科技是大中华区专注于无人化L4级技术的自动驾驶解决方案供应商,公司深耕自动驾驶领域十年,依托自主研发的U-Drive®智能驾驶平台,构建了覆盖感知、决策、控制全链条的核心技术体系,可灵活满足多场景、高级别的自动驾驶应用需求,筑牢技术壁垒。驭势科技自动驾驶解决方案拥有全场景通用适配能力,已规模化落地各类开放及封闭应用场景,覆盖机场、厂区、物流、营运及机动车辆等多元领域,同时囊括L2级至L4级全谱系自动驾驶级别,实现技术与应用场景深度融合,场景适配与落地能力行业领先。其中,公司在机场、工业园区等封闭核心赛道稳居行业龙头地位,依托传统封闭场景的先发优势与技术积淀,正稳步向外拓展,加速布局全域开放场景,构建全维度自动驾驶业务版图。凭借深厚的技术积累与精准的市场布局,驭势科技建立了稳固的行业地位。根据弗若斯特沙利文的资料,公司于2025年按收益计在大中华区封闭场景中商用车L4级自动驾驶解决方案市场的市场份额达3.1%,彰显了公司在核心细分领域的绝对领先优势。全场景深度布局,筑牢行业龙头地位在机场领域,驭势科技实现了行业突破性发展。根据弗若斯特沙利文的资料,公司是唯一一家为全球机场提供大型商业营运L4级自动驾驶解决方案的供应商,率先实现机场场景"去安全员"商业化运营。目前,公司已成功在香港国际机场部署无人电动牵引车、无人接驳车和无人巡逻车及相关软硬件,高效完成无人行李及货物牵引、旅客接驳、机场巡逻等核心服务,获得市场高度认可与赞誉。截至最后可行日期,公司已与17个中国机场及3个海外机场展开深度合作,同时公司一直在积极探索与中国及全球4个机场的合作机会,持续巩固在机场运输领域的领先地位,充分展现了解决方案及服务的可扩展性及适配性。在厂区领域,驭势科技聚焦无人化物流痛点,提供端到端无人化物流解决方案,成功实现从室内到室外、从室外到室内对原材料、样品、零件、半成品及制成品的全流程无人化交付,实现从受控厂区环境向开放道路应用的延伸,为产业物流升级提供了全新路径。在室内运作方面,公司的无人车无需依赖GPS,通过场景记忆技术实现精准作业;在室外运作方面,无人车可适应多种交通工况及全天候环境,具备极强的环境适应性。根据弗若斯特沙利文的资料,于2025年,公司成为提供可实现室内室外自主运作自动驾驶解决方案的最大L4级自动驾驶解决方案供应商之一,解决方案及服务广泛覆盖汽车、化工、光伏及锂电池制造等多个行业,为各行业客户降本增效、提升运营安全性提供了有力支撑。除已实现规模化落地的机场及厂区场景外,驭势科技还通过自动驾驶套件解决方案,将自动驾驶应用场景持续拓展至城市道路、港口、矿山、农场及牧场等多元领域,并将通用技术延伸到乘用车高阶智驾,获得头部主机厂的持续青睐,逐步构建起全场景自动驾驶生态,为未来发展开辟了更广阔的空间。技术引领口碑彰显,业绩稳步迈入增长通道依托全栈自研的核心技术、全场景的解决方案及成熟的商业化落地能力,驭势科技获得市场广泛认可,商业化落地成效显著。截至最后可行日期,公司已为6个国家及地区的249名客户部署解决方案及服务,其中包括35家《财富》中国及世界500强企业,技术实力、安全管控与品质标准均已达全球头部客户要求,并建立完善的数据合规管理体系,客户群体横跨多元行业领域,为公司持续发展奠定了坚实的客户基础。行业认可度持续提升的同时,驭势科技斩获多项重磅荣誉,先后入选福布斯中国最具创新力企业榜、《财富》中国最具社会影响力的创业公司及毕马威中国领先汽车科技企业50强,亦获《胡润百富》评为全球独角兽企业、《科创板日报》评为科创好公司。尤为值得一提的是,公司于2021年荣获国家重点专精特新"小巨人"企业称号,充分彰显了公司在技术创新与行业影响力方面的突出实力,成为行业创新发展的标杆。得益于行业政策红利持续释放、核心技术不断迭代升级及商业化规模稳步扩大,驭势科技近年来业绩保持稳步增长,展现出强劲的发展韧性与增长潜力。财务数据显示, 2023年至2025年公司营收从1.61亿元增至3.28亿元,同期,公司毛利从0.79亿元增至1.68亿元,2023-2025年复合增长率约42.7%,2022至2025年四年总营收增长超4倍,盈利能力持续提升,彰显了良好的经营质量。 总体而言,中国AI企业的未来蓝海与星辰大海,从来不止局限于国内市场,更在于走向全球、深耕国际舞台。驭势科技凭借硬核产品实力、完备的行业资质认证、成熟严苛的质量管理体系,以及完善的数据合规架构与全方位本地化服务体系,已获得全球行业顶尖客户的高度认可与深度信赖。未来,随着赴港上市的稳步推进,公司将借助资本的力量,持续加大技术研发投入,拓展更多应用场景,深化全球市场布局,推动公司业绩增长再上新台阶,其长期成长潜力值得市场高度期待。 Copyright 2026 亚太商讯 via SeaPRwire.com. All rights reserved. www.acnnewswire.com
More
Sherlocq Launches the First AI-Native Regulatory Intelligence Platform for Global Financial Services ACN Newswire

Sherlocq Launches the First AI-Native Regulatory Intelligence Platform for Global Financial Services

NEW YORK, USA AND ABU DHABI, UAE, May 13, 2026 - (ACN Newswire via SeaPRwire.com) - Sherlocq, the first AI-native regulatory intelligence platform for global financial services, today announced its public launch. Designed for compliance officers, lawyers, risk professionals, and regulators who operate at the intersection of law, governance, and institutional accountability, Sherlocq delivers regulatory intelligence that is precise, traceable, and usable at institutional scale.The launch marks the emergence of a new category in enterprise AI: regulatory intelligence, a vertical distinct from generic AI assistants, conventional regtech monitoring tools, and document management platforms. Sherlocq has been built from the ground up to meet the security, privacy, and domain standards that regulated institutions require, and which no general-purpose AI platform has been designed to deliver.THE PROBLEMFinancial institutions, law firms, regulators, and consultants collectively spend over $300 billion every year on regulatory compliance. More than ten million professionals carry the weight of that complexity daily, tracking regulatory changes across dozens of jurisdictions, reviewing thousands of documents, and making high-stakes decisions that can determine the fate of institutions and individuals alike.Until now, the tools available have been fundamentally inadequate: monitoring without interpretation, alerts without answers, search without synthesis. Regulatory research has remained a largely manual process for decades. Vertical AI has already demonstrated category-defining value in adjacent domains. Regulatory intelligence represents a larger, more global, and more complex opportunity.Sherlocq changes that.THE PLATFORMAt launch, Sherlocq covers the regulatory output of governments, supervisory authorities, and enforcement bodies across 30+ jurisdictions, including the US, UK, UAE, Singapore, and Hong Kong. It ingests, structures, and indexes this information continuously, so when a compliance officer, lawyer, or risk professional asks a question, Sherlocq returns a precise, sourced, and traceable answer in seconds. Research that previously required hours of manual work across multiple sources is completed in under a minute.The platform launches with three live capabilities:Regulatory Research and Analysis - Multi-jurisdiction research, cross-border regulatory comparison, compliance framework analysis, and obligation mapping across the full spectrum of financial services regulation, covering all major regulated financial centres.Document Intelligence - Structured review, gap assessment, benchmarking, and policy analysis against applicable regulatory standards, available on the native Sherlocq platform.Sanctions Intelligence - Real-time, multi-regime sanctions research across OFAC, OFSI, EU, UAE, and 320+ data sources in a single query, with full source traceability. The first AI-native platform to deliver this level of depth and auditability across multiple sanctions regimes simultaneously.Sherlocq is available on web, iOS, and Android, for individual professionals and enterprise organisations. AI connectors are live for Claude and ChatGPT, enabling regulatory research to be accessed directly within the tools professionals already use. Microsoft Copilot and Google Gemini integrations follow shortly.Sherlocq is certified to ISO 27001 and ISO 27701 standards, meeting the security and data privacy requirements of regulated financial institutions globally.FOUNDER'S STATEMENT"I have spent my career sitting across the table from regulators, leading investigations at the highest levels, and advising institutions in the most consequential moments of their existence. In every one of those engagements, the same problem recurred: brilliant professionals, at world-class institutions, spending most of their time on research and cross-referencing that should have been automated years ago. Not because the technology did not exist. Because no one had built it with the rigour, the domain depth, and the institutional trust that this work demands. That is what we built. Sherlocq is not a general AI tool adapted for compliance. It is the intelligence infrastructure that this industry has always needed and never had," said Bhavin Shah, Founder and Chief Executive Officer, Sherlocq.ABOUT THE FOUNDERBhavin Shah is a globally recognised regulatory and compliance leader with over twenty years of experience advising sovereigns, regulators, boards, and financial institutions across their most complex and politically sensitive challenges. His career spans multi-jurisdiction investigations, AML and financial crime reform, regulatory negotiations, crisis management, and governance advisory across the US, UK, Middle East, and Asia Pacific. He has advised some of the world's most consequential regulatory reform processes and financial institutions at moments of institutional stress, enforcement risk, and strategic transformation.Shah is a World Economic Forum Young Global Leader (2020), a board member of the D2A2 digital assets and AI policy forum, and holds executive education credentials from Harvard Business School and Harvard Kennedy School. He serves as an independent non-executive director on the boards of regulated financial institutions, giving him direct and ongoing insight into the governance, compliance, and regulatory pressures that Sherlocq is designed to address.INDUSTRY VOICES"Regulatory complexity has been accelerating for years and this is only compounding with the recent trends toward fragmentation around the globe. The tools available to compliance professionals have not kept pace. Sherlocq addresses that gap in a way that is substantive, not superficial. What distinguishes this platform is that it has been built with a genuine understanding of how regulated institutions work and what they actually need to be more effective and more efficient. The depth, the traceability, and the institutional-grade approach reflect the kind of rigour that regulators and boards rightly expect. I am proud to support Bhavin and the Sherlocq team as they bring this important product to market," said Bryan Stirewalt, Former Chief Executive, Dubai Financial Services Authority; Former National Bank Examiner, Office of the Comptroller of the Currency; Board Advisor, Sherlocq."Running a banking group across more than 35 markets meant living with regulatory complexity as a daily operational reality. Our teams were talented and diligent but the tools available forced them into a process that was slow, fragmented and heavily manual. Sherlocq solves that problem. It gives compliance and legal professionals the structured multi-jurisdictional intelligence that I would have wanted for my team. This is the platform the industry has always needed,” said Arnold Ekpe, Former Group Chief Executive Officer, Ecobank Group; Board Advisor, Sherlocq.ABOUT SHERLOCQSherlocq Inc. is a US-incorporated AI technology company (Delaware) with principal offices in New York and Abu Dhabi, UAE, and the creator of the first AI-native regulatory intelligence platform purpose-built for global financial services. The company has completed a pre-seed financing round backed by investors across the US, UAE, and Europe. Designed for compliance officers, lawyers, risk professionals, regulators, and governance teams, the platform delivers multi-jurisdiction regulatory research, document intelligence, and sanctions intelligence, with workflow automation and deeper enterprise capabilities on the near-term roadmap. Sherlocq is certified to ISO 27001 and ISO 27701 standards and is available globally on web, iOS, and Android. Financial institutions, law firms, and professional services organisations seeking enterprise access are invited to contact hello@sherlocq.com. sherlocq.com | sherlocq.ai | hello@sherlocq.com MEDIA CONTACTFor media enquiries, interview requests with Bhavin Shah, or access to additional materials including product demonstrations, founder biography, and platform assets:Press contact: press@sherlocq.com Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com
More
Agnete Kirk Kristiansen Appointed Chair of the LEGO Foundation ACN Newswire

Agnete Kirk Kristiansen Appointed Chair of the LEGO Foundation

BILLUND, DENMARK, May 13, 2026 - (ACN Newswire via SeaPRwire.com) - At the LEGO Foundation's annual meeting, the Board of Directors elected Agnete Kirk Kristiansen as Chair of the Board. As fourth generation member of the Kirk Kristiansen family, owners of the LEGO Group, she becomes only the fifth Chair of the Foundation since it was founded in 1986.Agnete Kirk Kristiansen has served as Deputy Chair of the LEGO Foundation since 2023 and replaces her brother Thomas Kirk Kristiansen who steps down to assume the position of Deputy Chair. In addition to her role at the LEGO Foundation, Agnete Kirk Kristiansen also serves as Deputy Chair of KIRKBI A/S, the family-owned holding and investment company that owns 75% of the LEGO Group.As ascending Chair, Agnete Kirk Kristiansen highlighted the role of the LEGO Foundation in building a brighter tomorrow for children around the world:I am truly honored to step into the role as Chair of the LEGO Foundation and to continue our important work for children. The foundation holds a very special place in our family and has done so ever since it was established more than 40 years ago. A deep sense of responsibility to make a positive difference for children runs through our family and I strongly believe that every child should have the opportunity to thrive and grow. I am proud to contribute to this mission and help carry it forward.The change in chair takes place the year after Agnete stepped into the role as chair of non-profit foundation Ole Kirk's Fond. With the transition, the fourth generation of the owner family is broadening its engagement and commitment to active ownership.Descending Chair Thomas Kirk Kristiansen said:It has been a privilege to chair the LEGO Foundation for the past 10 years, and I am very happy to now pass on the role to Agnete. She is deeply committed to the LEGO Foundation mission, and I know she will do her utmost to further the cause of securing a childhood for all. During her tenure as Deputy Chair, she has played an integral part in shaping the foundation's current strategy and as she steps into the role as Chair, we further widen the active ownership and engagement from the family across the LEGO ecosystem.Thomas Kirk Kristiansen has served as Chair of the LEGO Foundation since 2016 and in that period the foundation has committed grants of more than DKK 15 billion (EUR 2 billion) through partner organisations across the globe to improve children's outcomes.For 40 years, the LEGO Foundation has been focused on giving back and building a better world for children. We are very mindful of the trust families and communities place in us, and it is not a responsibility we take lightly. Even in the most challenging settings, the foundation can help put a smile on a child's face, lift up learners of all abilities and change life paths. We do so with the utmost sensitivity and responsibility, said Agnete Kirk Kristiansen.In addition to safeguarding the continued development and success of the LEGO Group as part-owner, the LEGO Foundation pursues its philanthropic mission to support initiatives within education, research, and child development through funding of and close collaboration with organisations such as Brac, IRC, UNICEF, Save the Children, Norwegian Refugee Council and others.Further changes to the LEGO Foundation BoardIn addition to Agnete and Thomas Kirk Kristiansen changing roles as Chair and Deputy Chair, the LEGO Foundation Board of Directors at its May meeting also elected as member of the Board Ingrid Stange, who brings a wealth of experience in philanthropy, education and non-profit leadership. Further, both Jørgen Vig Knudstorp, former CEO of the LEGO Group, and El Hadji Amadou Gueye Sy (As), former Secretary-General of the International Federation of Red Cross and Red Crescent Societies, left the Board after 16 and four years of service respectively to the LEGO Foundation.Thomas Kirk Kristiansen thanked the two departing Board members for their long-standing commitment to the foundation:We look very much forward to welcoming Ingrid, who brings highly complementary expertise to the board. At the same time, I thank As for bringing invaluable insights and experience to help shape our work.I would also like to extend my sincerest gratitude to Jørgen for his unwavering dedication to the foundation. During his extensive tenure, Jørgen has been instrumental in defining our vision and strategy while never losing sight of the children we are here to serve.Additionally, Malou Aamund, who has served on the Board since 2021, stepped into the role of Second Deputy Chair of the Foundation.Biography: Agnete Kirk KristiansenLEGO Foundation2026 - Chair of the Board of Directors2023 - 2026 Second Deputy Chair of the Board of DirectorsFrom 2008 Member of the Board of DirectorsKIRKBI A/S2024 - Deputy Chair of the BoardCentre for ADHD+, Aarhus, DenmarkFounderOle Kirk's Fond2025 - Chair of the BoardDegreePsychology, Aarhus University, 2010Additional roles, present and past:Executive Manager, KIRK83 Holding ApSMember of the Advisory Board, RucaRepresentative of the fourth generation of the LEGO owner familyExtensive experience in family-owned companies, long-term stewardship and board workLEGO Foundation Board of DirectorsAgnete Kirk Kristiansen - ChairThomas Kirk Kristiansen - First Deputy ChairMalou Aamund - Second Deputy ChairHilary Pennington - Member of the BoardIngrid Stange - Member of the BoardLEGO Foundation Board of Directors Chairs1986 - 1993: Gotfred Kirk Kristiansen (2nd-generation LEGO owner)1993 - 2000: Bent Skov2000 - 2016: Kjeld Kirk Kristiansen (3rd-generation LEGO owner)2016 - 2026: Thomas Kirk Kristiansen (4th-generation LEGO owner)2026 - Agnete Kirk Kristiansen (4th-generation LEGO owner)About LEGO Fonden:The LEGO Foundation is a Danish corporate foundation entrusted with 25 % ownership of the LEGO Group. The Foundation works with partners around the world to support children's needs and champion the dignity of childhood. Through both philanthropic donations and impact investments the Foundation exists to build the conditions and create the space for every child, everywhere, to thrive and grow. More information about the LEGO Foundation can be found at: https://www.legofoundation.com/Contact information:Mads Hvitved Grandmads.hvitved.grand@legofoundation.comSOURCE: LEGO Fonden Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com
More
Wellgistics Health Announces Pilot MSO Collaboration with Kare PharmTech Targeting $14 Billion U.S. Market for CCM and RPM Services ACN Newswire

Wellgistics Health Announces Pilot MSO Collaboration with Kare PharmTech Targeting $14 Billion U.S. Market for CCM and RPM Services

Highlights:According to third-party industry reports, the U.S. RPM market is currently $14 Billion alone and expected to reach approximately $29 Billion by 2030, representing a 12.6% CAGR, as healthcare providers continue shifting toward value-based and home-based care models¹Pilot initiative launched across multiple provider offices focused on chronic care management (CCM) and remote patient monitoring (RPM) through it's MSO infrastructureApproximately 1,500+ claims generated to date through the pilot infrastructure with expansion roadmap targeting additional providersWellgistics Pharmacy Network of 6,500+ independent pharmacies positioned to support patient engagement and care coordination initiativesParticipating pharmacists expected to gain access to new clinical service revenue opportunitiesTAMPA, FLA., May 13, 2026 - (ACN Newswire via SeaPRwire.com) - Wellgistics Health, Inc. (NASDAQ:WGRX) ("Wellgistics" or the "Company"), a leading healthcare technology and pharmaceutical distribution company, today announced a pilot collaboration with Kare PharmTech and Kare Clinicals integrating its MSO infrastructure to support chronic care management ("CCM") and remote patient monitoring ("RPM") services across participating provider offices. According to third-party industry reports, the U.S. RPM market is currently $14 Billion and expected to reach approximately $29 Billion by 2030, representing a 12.6% CAGR, as healthcare providers continue shifting toward value-based and home-based care models.¹The pilot program currently includes multiple provider offices, with Kare Clinicals MSO serving as the billing provider on behalf of participating offices and rendering providers. The initiative is designed to support patient engagement, care coordination, and longitudinal monitoring programs through scalable operational and technology-enabled workflows. All CCM and RPM services are expected to be furnished and billed by appropriately licensed providers and participating entities in accordance with applicable federal and state healthcare laws, reimbursement requirements, and payor program rules.The companies stated that the pilot infrastructure has already generated 1,500+ claims and is intended to serve as the foundation for broader expansion efforts targeting approximately additional providers over time. As part of the collaboration, Wellgistics Health intends to leverage its network of more than 6,500 independent pharmacies to help identify and support eligible patients who may benefit from CCM and RPM services. Participating pharmacies within the Wellgistics Pharmacy Network may also have opportunities to participate in clinical engagement initiatives associated with the program.Prashant Patel, President and CEO of Wellgistics Health, Inc., stated, "We believe the convergence of pharmacy engagement, provider connectivity, and technology-enabled care coordination represents a significant opportunity to improve patient outcomes while creating new economic opportunities for independent pharmacies. Through this pilot collaboration with Kare PharmTech, we are establishing infrastructure designed to support scalable patient engagement models across chronic care management and remote patient monitoring programs."Mital Panera, Founder and Chief Executive Officer of Kare PharmTech, added, "Our focus has been on building an operationally efficient MSO platform capable of supporting providers with care coordination and reimbursement workflows. By collaborating with Wellgistics Health and its pharmacy network, we believe we can further expand patient participation, improve continuity of care, and create a scalable framework for future provider growth."The companies noted that the pilot program remains subject to ongoing operational development, provider participation, and regulatory compliance considerations as expansion efforts continue.About Wellgistics Health, Inc.Wellgistics Health (NASDAQ:WGRX) is a health information technology leader, integrating proprietary pharmacy dispensing optimization artificial intelligence platform EinsteinRx™ into its patented blockchain-enabled smart contracts platform PharmacyChain™ to optimize the prescription drug dispensing journey. Its integrated platform connects 6,500+ pharmacies (the "Wellgistics Pharmacy Network") and 200+ manufacturers, offering wholesale distribution, digital prescription routing, direct-to-patient delivery, and AI-powered hub services such as eligibility, adherence, onboarding, prior authorization, and cash-pay fulfillment as needed to optimize patient access. Wellgistics provides end-to-end solutions designed to restore access, transparency, and trust in the U.S. prescription drug market for independent pharmacies.About Kare PharmTech, LLCKare Clinicals is part of the larger ecosystem of companies owned by Kare PharmTech, LLC, a company controlled by Dr. Kiran Patel. Dr. Patel founded Medicaid provider WellCare in 1992 and sold it in 2002 for $200 million. In 2007, Dr. Patel founded America's 1st Choice Holdings and acquired Freedom Health and Optimum Holdings. In 2017, he sold America's 1st Choice Holdings to Anthem, Inc. Dr. Patel is a noted philanthropist and was named Floridian of the Year by Florida Trend Magazine.Forward-Looking StatementsThis press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements regarding the Company's expectations, beliefs, plans, objectives, intentions, strategies, future events, or performance, including statements regarding the potential benefits, scalability, expansion, commercialization, provider participation, reimbursement opportunities, patient engagement initiatives, operational capabilities, and future development of the pilot collaboration with Kare PharmTech and Kare Clinicals, as well as the anticipated role of the Wellgistics Pharmacy Network in supporting CCM and RPM initiatives. Words such as "anticipate," "believe," "could," "expect," "intend," "may," "plan," "potential," "project," "seek," "should," "will," and similar expressions are intended to identify forward-looking statements.These forward-looking statements are based on current expectations and assumptions and involve risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. Such risks and uncertainties include, without limitation, risks relating to provider adoption and participation, reimbursement outcomes, patient engagement levels, operational execution, scalability of the pilot program, regulatory and healthcare compliance considerations, changes in applicable laws or reimbursement policies, market acceptance of the Company's services, competitive factors, and the Company's ability to develop and maintain strategic relationships and successfully implement its business strategy.The pilot collaboration described in this press release is exploratory in nature, and there can be no assurance that the initiative will result in expanded commercial relationships, material revenue opportunities, or long-term operational success.Additional information regarding these and other risks can be found in the Company's filings with the U.S. Securities and Exchange Commission, including the risk factors contained therein. The Company undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, except as required by law.Wellgistics Media & Investor ContactMedia: media@wellgisticshealth.comInvestor Relations: IR@wellgisticshealth.com[1] MarketsandMarkets - U.S. Remote Patient Monitoring Market ReportSOURCE: Wellgistics Health, Inc. Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com
More
Wellgistics Health宣布与Kare PharmTech开展MSO试点合作,瞄准美国价值140亿美元的慢性病管理(CCM)和远程患者监测(RPM)服务市场 ACN Newswire

Wellgistics Health宣布与Kare PharmTech开展MSO试点合作,瞄准美国价值140亿美元的慢性病管理(CCM)和远程患者监测(RPM)服务市场

重点:· 根据第三方行业报告,随着医疗服务提供者持续向价值导向型和居家护理模式转型,美国远程患者监测(RPM)市场目前规模已达140亿美元,预计到2030年将达到约290亿美元,复合年增长率(CAGR)为12.6%¹· 通过其MSO基础设施,在多家医疗机构启动了试点项目,重点关注慢性病管理(CCM)和远程患者监测(RPM)· 截至目前,通过该试点基础设施已产生约1,500余份理赔,且扩展路线图旨在覆盖更多医疗服务提供者· Wellgistics药房网络拥有6,500多家独立药房,可为患者参与和护理协调计划提供支持· 参与该计划的药剂师有望获得新的临床服务收入机会佛罗里达州坦帕市, 2026年5月13日 - (亚太商讯 via SeaPRwire.com) - 领先的医疗科技与药品分销公司 Wellgistics Health, Inc.(纳斯达克代码:WGRX)(以下简称“Wellgistics”或“公司”)今日宣布,将与 Kare PharmTech 和 Kare Clinicals 开展试点合作,整合其管理服务组织(MSO)基础设施,以支持参与该计划的医疗机构开展慢性病管理(“CCM”)和远程患者监测(“RPM”)服务。据第三方行业报告显示,随着医疗服务提供者持续向价值导向型和居家护理模式转型,美国远程患者监测市场目前规模为140亿美元,预计到2030年将达到约290亿美元,复合年增长率(CAGR)为12.6%。¹该试点项目目前涵盖多家医疗机构,由 Kare Clinicals MSO 代表参与的医疗机构及服务提供方负责账单处理。该计划旨在通过可扩展的运营流程和技术驱动的工作流,支持患者参与、护理协调及纵向监测项目。所有慢性病管理(CCM)和远程患者监测(RPM)服务均应由持有相应执照的医疗服务提供方及参与实体,根据适用的联邦和州医疗保健法律、报销要求以及支付方项目规则提供并进行结算。双方公司表示,试点基础设施已产生1,500多份索赔,并计划以此为基础,逐步扩大服务范围,未来将覆盖更多医疗服务提供者。作为合作的一部分,Wellgistics Health计划利用其覆盖6,500多家独立药房的网络,协助识别并支持可能从CCM和RPM服务中获益的符合条件患者。Wellgistics药房网络内的参与药房还可能有机会参与与该项目相关的临床参与计划。Wellgistics Health, Inc.总裁兼首席执行官Prashant Patel表示:“我们相信,药房参与、医疗服务提供者互联以及技术赋能的护理协调三者的融合,为改善患者预后创造了重要机遇,同时为独立药房开辟了新的经济机遇。通过与 Kare PharmTech 的此次试点合作,我们正在建立一套基础设施,旨在支持慢性病管理及远程患者监测项目中可扩展的患者参与模式。”Kare PharmTech 创始人兼首席执行官米塔尔·帕内拉补充道:“我们一直致力于构建一个运营高效的 MSO 平台,能够为医疗服务提供者提供护理协调和报销工作流支持。通过与Wellgistics Health及其药房网络合作,我们相信能够进一步扩大患者参与度、提升护理连续性,并为未来医疗服务提供者的业务增长构建可扩展的框架。”双方指出,随着扩展工作的持续推进,该试点项目仍需根据运营发展、医疗服务提供者的参与情况以及合规要求进行动态调整。关于 Wellgistics Health, Inc.Wellgistics Health(纳斯达克代码:WGRX)是一家健康信息技术领域的领导者,将专有的药房配药优化人工智能平台EinsteinRx™整合到其获得专利的基于区块链的智能合约平台PharmacyChain™中,以优化处方药配药流程。其集成平台连接了 6,500 多家药房(“Wellgistics 药房网络”)和 200 多家制造商,提供批发分销、数字处方路由、直接送达患者以及由人工智能驱动的枢纽服务,例如资格审核、用药依从性管理、新用户注册、预授权以及按需现金支付履约服务,以优化患者的用药获取渠道。Wellgistics 提供端到端解决方案,旨在为美国独立药房恢复处方药市场的可及性、透明度和信任。关于 Kare PharmTech, LLCKare Clinicals 隶属于 Kare PharmTech, LLC 旗下的企业生态系统,而 Kare PharmTech, LLC 由基兰·帕特尔(Kiran Patel)博士控制。帕特尔博士于 1992 年创立了医疗补助计划(Medicaid)服务提供商 WellCare,并于 2002 年以 2 亿美元的价格将其出售。2007年,帕特尔博士创立了America's 1st Choice Holdings,并收购了Freedom Health和Optimum Holdings。2017年,他将America's 1st Choice Holdings出售给Anthem, Inc.。帕特尔博士是一位知名慈善家,曾被《佛罗里达趋势》杂志评为“年度佛罗里达人”。前瞻性陈述本新闻稿包含《1995年私人证券诉讼改革法案》所界定的前瞻性陈述。前瞻性陈述包括关于本公司预期、信念、计划、目标、意图、战略、未来事件或业绩的陈述,包括关于与 Kare PharmTech 和 Kare Clinicals 开展试点合作所带来的潜在效益、可扩展性、扩展、商业化、服务提供商参与、报销机会、患者参与计划、运营能力及未来发展的陈述,以及 Wellgistics 药房网络在支持 CCM 和 RPM 计划方面预计将发挥的作用。诸如“预期”、“相信”、“可能”、“期望”、“打算”、“或许”、“计划”、“潜在”、“预测”、“寻求”、“应当”、“将”等词语及类似表述旨在识别前瞻性陈述。这些前瞻性陈述基于当前的预期和假设,涉及可能导致实际结果与这些陈述所表达或暗示的结果存在重大差异的风险和不确定性。此类风险和不确定性包括但不限于:与医疗服务提供者的采用和参与相关的风险、报销结果、患者参与度、运营执行、试点项目的可扩展性、监管和医疗保健合规性考虑、适用法律或报销政策的变更、市场对公司服务的接受度、竞争因素,以及公司建立和维持战略关系并成功实施其业务战略的能力。本新闻稿所述的试点合作具有探索性质,无法保证该举措将带来更广泛的商业关系、重大的收入机会或长期的运营成功。有关这些及其他风险的更多信息,可查阅本公司向美国证券交易委员会提交的文件,包括其中所载的风险因素。除法律要求外,本公司不承担因新信息、未来事件或其他原因而更新或修订任何前瞻性陈述的义务。Wellgistics 媒体与投资者联系方式媒体:media@wellgisticshealth.com投资者关系:IR@wellgisticshealth.com[1] MarketsandMarkets - 美国远程患者监测市场报告来源:Wellgistics Health, Inc. Copyright 2026 亚太商讯 via SeaPRwire.com. All rights reserved. www.acnnewswire.com
More
S&P Tear Sheet: GTJAI Continues to Play a Key Role in the Group’s International Strategy ACN Newswire

S&P Tear Sheet: GTJAI Continues to Play a Key Role in the Group’s International Strategy

HONG KONG, May 13, 2026 - (ACN Newswire via SeaPRwire.com) - Recently, in its latest Tear Sheet, S&P Global stated that it expects Guotai Junan International Holdings Limited (“Guotai Junan International” or “GTJAI”, Stock Code: 1788.HK), a subsidiary of Guotai Haitong Group, and its intermediate holding company Guotai Haitong Financial Holdings Ltd. (“GTHTFH”), to continue to play a key role in the international strategy of their ultimate parent Guotai Haitong Securities Co. Ltd. (“GTHT”).In its Tear Sheet, S&P Global pointed out that the business synergies between GTJAI and its parent company, particularly in investment banking and wealth management, reinforce its importance within the group. International development is one of GTHT’s core strategic priorities, and GTJAI will continue to play a key role in the Group’s efforts to strengthen its global presence. In 2025, GTJAI and GTHTFH recorded 284% and 85% profits growth, respectively, and accounted for about 3% and 8% of GTHT’s net profit during the year. This strong financial performance robustly demonstrates the Company’s contribution to the overall business of the Group.S&P Global expects that GTJAI will remain one of the Group’s core subsidiaries over the next two years and will continue to receive support from GTHT, with its issuer credit rating and “stable” outlook moving in tandem with those of the parent. S&P Global believes that GTJAI has access to timely parental support, including indirect benefits from the Shanghai government through GTHT if needed.This Tear Sheet fully reflects the Company’s current situation and expectations for future development. GTJAI will resolutely align with the Group’s international strategy, continuously enhance its own professional capabilities and the efficiency of business synergies with the Group, and contribute to Guotai Haitong Group’s goal of becoming a first-class investment bank with international competitiveness and market leadership.Note: This article is based on an independent opinion document (Tear Sheet: Guotai Junan International Holdings Ltd. And Guotai Haitong Financial Holdings Ltd.) published by S&P Global Ratings on May 5, 2026. This document does not constitute a rating action.About GTJAIGuotai Junan International (Stock Code: 1788.HK), a subsidiary of Guotai Haitong Group, is the market leader and first mover for internationalization of Chinese Securities Company as well as the first Chinese securities broker listed on the Main Board of The Hong Kong Stock Exchange through initial public offering. Based in Hong Kong with subsidiaries in Singapore, Vietnam and Macau, GTJAI’s business covers major markets around the world, offering high-quality and diversified comprehensive financial services for clients' overseas asset allocation. Core business includes wealth management, institutional investor services, corporate finance services, investment management and other business. GTJAI has been assigned “Baa2” and “BBB+” long term issuer rating from Moody and Standard & Poor respectively, as well as an MSCI ESG “AAA” rating, Wind ESG “A” rating and SynTao Green Finance “A” rating in ESG. Additionally, its S&P Global ESG score leads 81% of its global peers. The controlling shareholder, Guotai Haitong Securities (Stock Code: 601211.SH/ 2611.HK), is the comprehensive financial provider with a long-term, sustainable and overall leading position in the China’s capital markets. For more information about GTJAI, please visit https://www.gtjai.com. Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com
More
标普简报-国泰君安国际继续在集团国际化战略中发挥关键作用 ACN Newswire

标普简报-国泰君安国际继续在集团国际化战略中发挥关键作用

香港, 2026年5月13日 - (亚太商讯 via SeaPRwire.com) - 近日,标普全球(S&P Global)在其发布的最新简报中明确表示,预计国泰海通集团下属公司国泰君安国际控股有限公司(“国泰君安国际”、“公司”,股份代号:1788.HK)及其直接控股公司国泰海通金融控股有限公司(“国泰海通金控”)作为母公司国泰海通证券股份有限公司(“国泰海通”)核心子公司,将继续在集团国际化战略中发挥关键作用。标普全球在简报中指出,国泰君安国际与母公司在投资银行及财富管理领域的业务协同效应显著,进一步强化了其在集团内部的重要性。国际化发展为国泰海通的核心战略重点之一,国泰君安国际将继续在集团加强全球布局的过程中扮演关键角色。2025年,国泰君安国际及国泰海通金控分别实现利润增长284%及85%,分别占国泰海通证券当年净利润约3%及8%。这一强劲的财务表现,有力印证了公司对集团整体业务发展的贡献。标普全球预期,国泰君安国际未来两年仍将作为集团核心子公司之一,持续获得母公司支持,其发行人信用评级及“稳定”展望将与母公司保持同步。标普全球认为,公司可获得母公司稳定、及时的支持,包括在必要时通过国泰海通间接受益于上海政府的资源。这份简报充分反应了公司的现况及对未来发展的预期。国泰君安国际将坚定不移地配合集团国际化战略,持续提升自身的专业能力及与集团的业务协同效率,为国泰海通集团成为具备国际竞争力与市场引领力的一流投资银行作出贡献。注:本文内容基于标普全球评级于2026年5月5日发布的独立观点文件(Tear Sheet:Guotai Junan International Holdings Ltd. And Guotai Haitong Financial Holdings Ltd.),该文件不构成评级行动。关于国泰君安国际国泰海通集团下属公司国泰君安国际(股票代号:1788.HK),是中国证券公司国际化的先行者和引领者,公司是首家通过IPO于香港联合交易所主板上市的中资证券公司。国泰君安国际以香港为业务基地,并在新加坡、越南和澳门设立子公司,业务覆盖全球主要市场,为客户境外资产配置提供高质量、多元化的综合性金融服务,核心业务包括财富管理、机构投资者服务、企业融资服务、投资管理等。目前,国泰君安国际已分别获得穆迪和标准普尔授予“Baa2”及“BBB+”长期发行人评级,MSCI ESG“AAA”评级, Wind ESG“A”评级及商道融绿ESG“A”评级,同时其标普全球ESG评分领先全球81%同业。公司控股股东国泰海通证券(股票代号:601211.SH/2611.HK)为中国资本市场长期、持续、全面领先的综合金融服务商。更多关于国泰君安国际的信息请见:https://www.gtjai.com Copyright 2026 亚太商讯 via SeaPRwire.com. All rights reserved. www.acnnewswire.com
More
Asia Summit on Global Health and Hong Kong International Medical and Healthcare Fair concluded successfully ACN Newswire

Asia Summit on Global Health and Hong Kong International Medical and Healthcare Fair concluded successfully

HONG KONG, May 13, 2026 - (ACN Newswire via SeaPRwire.com) - The sixth Asia Summit on Global Health (ASGH), jointly organised by the Government of the Hong Kong Special Administrative Region and the Hong Kong Trade Development Council (HKTDC), and the 17th Hong Kong International Medical and Healthcare Fair (Medical Fair), organised by the HKTDC and co-organised by the Hong Kong MedTech Association, have concluded successfully. As one of the two flagship events of International Healthcare Week, the ASGH gathered some 3,000 participants from 43 countries and regions and arranged over 400 one‑on‑one deal-making meetings, while also facilitating the signing of multiple cooperation agreements, with a strong focus on the application of artificial intelligence. Meanwhile, the Medical Fair welcomed some 13,000 buyers from 61 countries and regions for sourcing and networking. More than 670 business matching meetings were arranged during the fair, supporting buyers and exhibitors in identifying potential partners and advancing concrete business discussions. Together, the two flagship events facilitated over 1,000 high-quality collaborations and connections, fully demonstrating the synergy between medical technology, investment and industry applications.Over 90 global leaders share insight into healthcare innovation development and AI applicationsThe sixth ASGH, a two-day event jointly organised by the Government of the Hong Kong Special Administrative Region and the HKTDC, has concluded under the theme Fuelling Healthcare Breakthroughs, focusing on public health, frontier healthcare technologies, AI breakthroughs, healthcare investment and the silver health. The ASGH brought together over 90 international healthcare officials, scientific pioneers, Nobel laureate, investors and corporate leaders to share insight and explore pathways to accelerate innovation across the global healthcare ecosystem.At Plenary Session I – Strengthening Pandemic Preparedness through Global Collaboration. Prof Ibrahim Abubakar, Vice‑Provost (Health) and Professor of Infectious Disease Epidemiology, University College London, said: “Research platforms need to be developed long in advance of pandemics, and we must invest in infectious disease infrastructure, and beyond, whether it’s in AI technology or in disease management.”Plenary Session II – Fuelling Healthcare Breakthroughs centred on the commercialisation of medical research, biomedical innovation and healthcare investment opportunities. Jonathan Symonds, Chair of GSK, said: “All developed countries are now facing ageing, low birth rates and an increasing impact of chronic disease. So, it's no longer just a health system problem, but it's now an economic problem.”During the Dialogue with Global Pioneer in Health session, Prof Michael Levitt, 2013 Nobel Laureate in Chemistry and Robert W and Vivian K Cahill Professor of Cancer Research at the Stanford University School of Medicine, said that Hong Kong’s healthcare system possesses unique advantages and high-quality statistical data, making it potentially more valuable for research than the US and other countries or regions, in areas such as longevity.The ASGH featured multiple thematic sessions spotlighting the application of AI in healthcare. Sustaining the momentum of the “Intelligence at Scale: How AI is Powering Real-World Healthcare Revolution” session on the first day, another thematic session on the second day, “Transforming Healthcare through Digital Health & AI Innovations”, explored how digital technologies and artificial intelligence are reshaping healthcare systems. Natasha Chhatrapati, Senior Director, Business Transformation Lead for International, Pfizer Inc., said: “AI is compressing timelines across the entire healthcare journey, from drug development and clinical research to how we engage with physicians and how patients consume care.”The session “The Next Frontier in China’s Healthcare Industry” examined strategies to advance the Chinese Mainland healthcare sector. Dr James Xue, Founder, Chairman and CEO of CANbridge Pharmaceuticals Inc, said: “China has an edge because of the population. A bigger population base will allow companies to build better drug candidates.”With silver health emerging as a major global focus, the Silver Health Chapter included the session “Unlocking Growth in Silver Health: From Precision Medicine to Smart Ageing Innovations”, which brought together leading experts to discuss challenges and opportunities arising from population ageing. Dr Alex Mihailidis, Associate Vice‑President, International Partnerships and Professor at the University of Toronto and Scientific Director at AGE‑WELL, provided in‑depth insight into breakthroughs in prevention and treatment of age‑related diseases, offering guidance for the development of the silver health economy and smart ageing solutions. He said: “For a technology to be successful with older people, it’s not just the technology, but also the service delivery model, as well as the practice and policy.”The newly introduced session “CSO Insights: Catalysing Scientific Breakthroughs and Investments for Future Health” featured discussions on research strategy and the acceleration of scientific discoveries into practical applications. Dr Li Xiang, Senior Vice President, Co-President and Chief Scientific Officer, Innovative Medicines Division, Fosun Pharma, said: “In our business, it is very important to begin with the end in mind. When you set out to do your discovery program, you must already know what the unmet needs are and how difficult the clinical trials will be.”Over 400 deal‑making sessions drive investment and business matchingBeyond thought leadership, the ASGH continued to serve as an effective platform for deal‑making and investment matching. Dedicated deal-making at the ASGH facilitated one‑to‑one meetings to promote tangible collaboration.During the ASGH, over 400 business and investment matching meetings were arranged, attracting investment institutions and healthcare enterprises from Europe, the US, Asia and the Guangdong‑Hong Kong‑Macao Greater Bay Area to explore opportunities in investment, technology deployment and market expansion.Colin Tan, Director of Operations at TusPark Holdings, an investor from the UK, said: “This year, I brought around 15 UK healthcare and life sciences companies to exhibit at the UK Pavilion. The ASGH has been an excellent platform to forge such connections. We are now facilitating a significant partnership in cancer research between a leading UK organisation and a Hong Kong counterpart.”ASGH also featured the ASGH Business Hub and the InnoHealth Showcase, bringing together some 180 healthcare innovation companies from 12 countries and regions to present cutting‑edge solutions across biotechnology, digital health and medical technologies.Strategic Partner of this year’s Summit, Shanghai Industrial Investment (Holdings) led multiple subsidiaries in exhibiting at the ASGH. Gu Feng, Chief Finance and Investment Officer, said that the ASGH fully showcased Hong Kong’s international competitiveness: “Chinese companies expanding overseas will come to Hong Kong, and foreign companies seeking to procure will do the same. Here we can not only acquire resources, but also connect and match resources, talent, capital, and other key elements.”AQ Biotech from Finland, exhibiting at ASGH for the first time, said that their objective was to explore the Asian market. They view Hong Kong as a vital hub that adds internationally recognised credibility, connectivity and commercial acumen, helping them take their work global.Dr Iman Manavitehrani, Founder and Director of SDIP Innovations, the Australian exhibitor returning for the second year, said: “Last year’s visit led directly to an IGNITE grant from HSITP, and we are now part of the first Australian cohort based here. With Hong Kong as our gateway to the GBA and Chinese Mainland, I am confident the connections made at the ASGH will lead to further collaboration and partnership.”Third-time exhibitor, Prof Leung Kam-tong, Founder and CEO of local healthcare startup Homing Pharmaceuticals, said: “We’ve already reconnected with three investors here for in-depth discussions on our fundraising strategy, taking our navigated CAR-T therapy to first-in-human clinical trials. Sessions outside my field sparked new ideas around refining the therapy and exploring new directions. I also met professors from Australia and Singapore, and look forward to exploring international R&D collaborations as we bring this therapy worldwide.”Building bridges for “go global” and other cross‑border healthcare collaborationsBuilding on its track record of facilitating collaboration, the ASGH enabled the signing of 10 Memoranda of Understanding (MoUs), such as those between the HKSH Medical Group and Siemens Healthineers, as well as Australian AI-powered clinical documentation platform startup Heidi Health, which signed separate agreements with local medical group EC Healthcare and Hong Kong Metropolitan University. These collaborations will drive deeper cooperation, including AI‑enabled healthcare applications and clinical research, further reinforced the ASGH’s role as a bridge connecting the Chinese Mainland and international healthcare ecosystems. Notably, HKSH Medical Group and Siemens Healthineers signed an agreement, formally establishing HKSH as Siemens Healthineers’ first Photon Counting Computed Tomography Simulation (PCCT-Sim) Reference Site in Asia.On the second day, the GoGlobal CONNECT series: Hong Kong as a Superconnector to Empower Global Expansion of Pharmaceutical Enterprises workshop brought together experts in regulation, clinical trials, IP protection and distribution to share practical insight on international expansion. Prof Bernard Cheung, Chief Executive Officer, Greater Bay Area International Clinical Trial Institute, said: “Public hospitals in Hong Kong have very good electronic medical records that go back 30 years. It’s a unique asset that benefits not just people in Hong Kong but the world, as it allows us to study the long-term progression of diseases.”The ASGH also featured the “GoGlobal Connect” and the Business of Healthcare Advisory Zone, enabling healthcare enterprises to connect with service providers and receive practical support for developing “go global” strategies. Xiang Jun, Chairman of 365 Intelligence (Beijing) Medical Technology Co., Ltd, said that the ASGH helped them gain a deeper understanding of Hong Kong’s professional services and of HKTDC’s “GoGlobal Connect” initiative. The company is particularly interested in Hong Kong’s research data and service resources, and plans to establish research operations in Hong Kong in the long term. Mark Xu, Regional Director of Sales and Marketing, Guangzhou Wondfo Biotech Co, Ltd, also successfully connected with service providers, including DKSH and the Greater Bay Area International Clinical Trial Institute, through this workshop. They engaged in in-depth discussions on potential collaboration opportunities for “going global”.During the summit, the HKTDC signed a Memorandum of Understanding with the Hong Kong Singapore Business Association (HSBA), supporting Mainland enterprises’ “going global” via Hong Kong to target the Singapore and ASEAN markets. Prime Minister and Minister for Finance of Singapore Lawrence Wong visited Hong Kong in March this year, during which both governments agreed to deepen cooperation. The HSBA and the HKTDC, together with professional service providers, plan to strengthen trade and economic ties between the two cities. By leveraging their respective strengths and promoting complementary cooperation, they aim to drive business development, assist Chinese Mainland enterprises in expanding regionally and internationally, and enhance tripartite collaboration among Singapore, Hong Kong, and the Chinese Mainland.The Medical Fair brings together global industry players to foster diverse collaborations, strengthening Hong Kong’s status as a global healthcare hubThe Medical Fair was being held concurrently. Organised by the HKTDC and co-organised by the Hong Kong MedTech Association, the Medical Fair adopted the theme Innovations Boosting Smart Health Experience. Focusing on three key areas: MedTech, GeronTech, and Preventive Healthcare, the event provided a high-efficiency trade and matchmaking platform for global R&D institutions, manufacturers, and medical professionals to showcase the latest industry trends. The number of exhibitors featuring smart ageing products and green solutions doubled this year, with many showcasing innovative solutions integrating AI and robotics to meet evolving market demands.The Medical Fair featured some 300 exhibitors from 10 countries and regions, including Hong Kong, Chinese Mainland, Macao, Taiwan, Australia, Canada, Korea, New Zealand, United States and Vietnam. The Fair featured seven major zones, including Startup Zone, Hospital Equipment and Digital Health, Biotech and Lab Diagnostics, Laboratory Technologies and Healthcare Services, Medical Supplies, and the World of Health and Wellness, showcasing the latest medical technologies and innovative solutions. Pavilions from leading local universities, the Hong Kong Science and Technology Parks, and the Hong Kong MedTech Association underscored a multi-sector commitment to fostering collaborative innovation across government, industry, academia, research, and investment sectors.Exhibitors acknowledged that AI has become a core driver of healthcare services, while the Medical Fair serves as a one-stop platform that brings together a complete healthcare ecosystem, successfully integrating AI, robotics technology and a wide range of smart medical devices. Wong Cheung Hang, Sales and Marketing Manager of Health Care & Co, a medical and rehabilitation equipment company in Hong Kong, said, “Buyers showed particular interest in our AI management systems, AI-assisted robots and various smart healthcare applications. With healthcare providers increasingly adopting smart health solutions, the market outlook is promising. We expect this fair to drive at least 20% business growth compared with last edition and enable us to promote smart rehabilitation technologies.” Many overseas exhibitors succeeded in securing business matching opportunities at the fair. Peter Li, Chief Executive Officer of first-time exhibitor GenomeMe Lab Inc from Canada, said, “We connected with buyers from Hong Kong, Thailand and India, and identified potential local partners in the healthcare and hospital sectors. This will help us explore entry into hospital channels, establish distribution networks, and lay the groundwork for future expansion into Southeast Asia, Australia and Korea.”The Medical Fair has facilitated numerous cross-regional collaborations, serving as a key platform for industry exchange and business matching. Dresio Limited, participating in the Fair for the third time under the banner of Hong Kong Science and Technology Parks, showcased its contactless physiotherapy assessment system Accudex, drawing strong interest from buyers across Hong Kong, Chinese Mainland, Singapore and the Philippines. Curtis Wong, Chief Operating Officer and Head of Research and Development of the company, said, “This year’s fair outperformed previous editions in footfall, business exchanges and partnership discussions. We have engaged with a large number of high-quality buyers from hospitals, rehabilitation centres and the insurance sector.” The company met with a Filipino buyer on the first day of the exhibition and subsequently signed a Memorandum of Understanding (MOU) on the third day, expanding its software into Southeast Asia, with the contract value expected to exceed HK$1 million.The Medical Fair was held concurrently with the ASGH and the Hospital Authority (HA) Convention, bringing together key industry stakeholders and generating strong synergy. Exhibitors were able to seize the opportunity to meet with numerous representatives from the Hospital Authority and major healthcare institutions, fostering meaningful exchanges and collaboration. Among them, first-time exhibitor PalmX Technology Limited showcased its palm vein biometric technology at the Startup Zone. Jeffrey Lo, Vice President of the company, was impressed by the Fair’s response, which exceeded his expectations. He added that within the first two days, they received over 20 enquiries from hospitals and healthcare institutions, including representatives from the Hospital Authority, and attracted interest from overseas buyers in Thailand, Indonesia, the Philippines and India, with potential orders ranging from US$10,000 to several hundred thousand dollars.This year’s Medical Fair attracted a significant number of buyers from emerging markets seeking sourcing opportunities. Dr Keo Sovann, an otorhinolaryngologist from Orchid Hospital in Cambodia who visited the fair specifically for new medical equipment, said, “I met more than 10 exhibitors from Chinese Mainland, Australia and Malaysia, which has helped expanding our hospital’s procurement network and advanced our internationalization efforts. I am particularly interested in a Hong Kong company’s AI-powered medical imaging solutions and X-ray equipment; we are considering an order of 20 units.” A buyer from Morocco also attended the fair for the first time to source laboratory equipment. Rachid Zemmouri, Business Development Manager of Promamec, said he met with at least 15 exhibitors from Hong Kong, Chinese Mainland, Taiwan and Indonesia. Discussions are underway on thermodynamics-related solutions with the aim of application to eye-disease treatment. Subject to satisfactory progress, he plans to invite partners to Morocco for site visits. He added that the company has an annual procurement budget of approximately US$70 million and intends to return for future sourcing.The Fair hosted over 50 themed forums and seminars, with leading technology companies, industry experts and academics sharing the latest industry trends, technological innovations and practical insights to foster in-depth exchange, collaboration and inspire trade buyers. Highlight sessions included “Accelerating Mental Health Innovation through AI Research and Adoption”, “HKMTA Medical Fair Forum 2026: The Medtech Solutions - Greater Bay Area & Overseas”, “The ASEAN Gateway: Navigating Regulations, Capital and Distributions from Hong Kong”, and “Decoding the Demand for Gerontechnology” among others, all of which attracted strong audience engagement. Selected sessions are available for replay on the Fair’s website for extended engagement.The exhibition continued to adopt the EXHIBITION+ hybrid model. Global exhibitors, industry professionals, and buyers could make use of the Click2Match and explore sourcing opportunities via HKTDC Sourcing. Click2Match will remain available until 20 May.Photo download: https://bit.ly/4nokRfTThe sixth Asia Summit on Global Health was attended by some 3,000 participants from 43 countries and regions.Dr Alex Mihailidis, Associate Vice President, International Partnerships and Professor at the University of Toronto and Scientific Director at AGE WELL, attended and shared his insight.In the session Transforming Healthcare through Digital Health & AI Innovations, Natasha Chhatrapati, Senior Director, Business Transformation Lead for International at Pfizer Inc, engaged with fellow panellists to examine the practical implementation and the latest breakthroughs in AI within the healthcare sector.On the second day, the GoGlobal CONNECT series: Hong Kong as a Superconnector to Empower Global Expansion of Pharmaceutical Enterprises brought together experts in regulation, clinical trials, IP protection and distribution to share practical insights on international expansion.During the ASGH, over 400 business and investment matching meetings were arranged, attracting investment institutions and healthcare enterprises from Europe, Asia and the Guangdong‑Hong Kong‑Macao Greater Bay Area to explore opportunities in investment, technology deployment and market expansion.The ASGH also featured the ASGH Business Hub and the InnoHealth Showcase, bringing together around 180 healthcare innovation companies from 12 countries and regions to present cutting‑edge solutions across biotechnology, digital health and medical technologies.The ASGH also featured the “GoGlobal Connect” and the Business of Healthcare Advisory Zone, enabling healthcare enterprises to connect with service providers and receive practical support for developing “go global” strategies.HKTDC signed a Memorandum of Understanding with the Hong Kong Singapore Business Association (HSBA), supporting Mainland enterprises to “go global” via Hong Kong and target the Singapore and ASEAN markets.The 17th Hong Kong International Medical and Healthcare Fair attracted buyers from 61 countries and regions, with some 13,000 buyers visiting the fair for sourcing and procurement.The Hong Kong MedTech Association led some 20 companies to exhibit at the fair, drawing strong buyer interest and encouraging in‑depth business discussions.The Canada Pavilion brought together a number of companies to promote their medical equipment, technology application solutions and related services, attracting buyers to explore opportunities and engage in business discussions.Hong Kong Science and Technology Parks Corporation led over 30 innovation and technology companies to exhibit at the Fair, showcasing the strength of Hong Kong’s local medical innovation and R&D capabilities.Industry experts at the themed session “ASEAN Gateway: Navigating Regulations, Capital and Distributions from Hong Kong” shared the latest market trends, fostering active exchanges among industry stakeholders.WebsitesInternational Healthcare Week: https://internationalhealthcareweek.hktdc.com/enAsia Summit On Global Health: https://www.asiasummitglobalhealth.com/conference/asgh/enHong Kong International Medical and Healthcare Fair: https://www.hktdc.com/event/hkmedicalfair/enList of Product: https://www.hktdc.com/event/hkmedicalfair/en/product Media enquiriesYuan Tung Financial Relations:Jasmine ZhangTel: (852) 3428 3278Email: jzhang@yuantung.com.hkLouise SongTel: (852) 3428 5691Email: lsong@yuantung.com.hkTiffany LeungTel: (852) 3428 2361Email: tleung@yuantung.com.hkHKTDC’s Communications & Public Affairs Department:Noah QiuTel: (852) 2584 4575Email: noah.yl.qiu@hktdc.orgNavin LawTel: (852) 2584 4525Email: navin.cm.law@hktdc.orgSerena CheungTel: (852) 2584 4137Email: jane.mh.cheung@hktdc.orgAbout HKTDCThe Hong Kong Trade Development Council (HKTDC) celebrates its 60th anniversary this year. The HKTDC is a statutory body established in 1966 to promote, assist and develop Hong Kong's trade. With over 50 offices globally, including 13 in the Chinese Mainland, the HKTDC promotes Hong Kong as a two-way global investment and business hub. The HKTDC organises international exhibitions, conferences and business missions to create business opportunities for companies, particularly small and medium-sized enterprises (SMEs), in the mainland and international markets. The HKTDC also provides up-to-date market insights and product information via research reports and digital news channels. For more information, please visit: www.hktdc.com/aboutus. Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com
More
SAP Unveils the Autonomous Enterprise ACN Newswire

SAP Unveils the Autonomous Enterprise

ORLANDO, May 13, 2026 - (ACN Newswire via SeaPRwire.com) - At SAP Sapphire in 2026, SAP SE (NYSE: SAP) introduced the Autonomous Enterprise to help enhance the world’s most critical business workflows, so that humans and AI work together to meet the accelerating demands of global business profitably, strategically and safely. “For the mission-critical processes of our customers,‘almost right’just isn’t good enough,” said Christian Klein, CEO of SAP SE,“By uniting SAP Business AI Platform with SAP Autonomous Suite, we anchor AI agents in the business processes, data and governance so they can deliver accurate, compliant and secure outcomes, unlocking new sources of revenue and meaningful cost savings.”The Autonomous Enterprise includes a unified AI platform for building, contextualizing and governing agents, an autonomous suite that executes core business operations and a new user experience that redefines how people work with enterprise software.Introducing SAP Business AI PlatformSAP Business AI Platform is a new foundation for building and deploying enterprise AI grounded in real business context. SAP Business AI Platform now unifies SAP Business Technology Platform, SAP Business Data Cloud and SAP Business AI into a single, governed environment.At its core is the SAP Knowledge Graph solution, which gives AI agents a structured map of business entities, processes and relationships across a customer’s SAP landscape. Joule Studio is SAP’s AI-first solution for building enterprise agents, applications and agentic workflows. Developers can build using the no-code, pro-code and AI frameworks of their choice on SAP-managed infrastructure that is secure, scalable and optimized for enterprise AI.Deploying SAP Autonomous Suite Across Every Business Function and IndustryBuilding on this foundation, SAP also introduced SAP Autonomous Suite, which enables SAP’s existing business applications with AI agents capable of running processes from start-to-finish.The suite will deploy more than 50 domain-specific Joule Assistants across finance, supply chain, procurement, human capital management and customer experience. These assistants will automate end-to-end processes by orchestrating a subset of over 200 specialized agents to execute precise tasks. For example, the new Autonomous Close Assistant can compress the financial close process from weeks to days by automating journal entries, reconciliation and error resolution across the entire process.SAP also launched Industry AI, expanding its deep industry portfolio through seven autonomous solutions that will enable start-to-finish industry processes and embed sector-specific process logic, data models and regulatory requirements. At SAP Sapphire, SAP showcased its work with European energy giant RWE to leverage Industry AI, helping reduce unplanned downtime across its offshore wind turbines. With SAP’s Autonomous Asset Management scenario, AI agents are designed to analyze data from thousands of past incidents, identify the likely root cause and generate pre-filled work orders with the right tools and proven fixes from other sites.Designing the Autonomous User ExperienceThe company also revealed Joule Work, redefining how users engage with SAP software. Instead of navigating individual applications and entering data across several screens, users will now interact primarily with Joule. By describing a desired business outcome, Joule will orchestrate the right combination of workflows, data and agents to get it done.Joule Work goes beyond conversation, proactively surfacing relevant insights and automating routine tasks behind the scenes so work moves forward even when humans aren’t actively steering it. It will be available on desktop, mobile and voice across SAP and non-SAP systems.Accelerating the Customer Journey Toward Autonomy with €100 Million InfusionSAP evolved its customer and partner programs to help accelerate the organization’s journey to the Autonomous Enterprise. To catalyze adoption, the company has launched a €100 million fund for SAP partners to help customers deploy SAP-built AI assistants and agents. The fund is also available to partners that extend or build new partner agents on the new SAP Business AI Platform using Joule Studio.SAP has enhanced its RISE with SAP and SAP GROW offerings to accelerate AI adoption. Both include access to the Joule Assistants portfolio; RISE with SAP customers will have three assistants activated within their first year, while SAP GROW customers receive full portfolio access at onboarding. SAP S/4HANA on-premises and SAP ERP Central Component (SAP ECC) customers are not excluded: those that commit to transitioning the majority of their current landscape to SAP Cloud ERP gain access to select AI scenarios, bridging the gap between their current landscape and their cloud destinationSAP also introduced new agent-led transformation tooling that can reduce ERP migration efforts by more than 35 percent, driving faster and more predictable projects by automating system analysis, code remediation, configuration and testing at scale.Lastly, SAP announced a full slate of strategic partnerships across each category:- Platform and suite partnerships include Anthropic, with Claude among the foundation models SAP’s AI platform will leverage to power Joule agents across HR, procurement and supply chain; Amazon Web Services, bringing zero-copy data integration between SAP Business Data Cloud and Amazon Athena; Google Cloud and Microsoft, enabling bidirectional agent-to-agent interoperability between Joule and external agent frameworks; Mistral AI and Cohere, delivering sovereign model options on SAP’s cloud infrastructure; n8n, providing visual AI workflow orchestration inside Joule Studio; NVIDIA, whose OpenShell provides the trusted secure runtime for Joule Studio; and Parloa, bringing AI agents into SAP Service Cloud to handle customer interactions with full access to business data and service processes.- Implementation partnerships include Palantir and Accenture, partnering on complex data migration scenarios, and Conduct for AI-powered cloud ERP migrations.Learn more in the SAP Sapphire 2026 Innovation News Guide.Visit the SAP News Center. Get SAP news via LinkedIn and Bluesky.Photo download: https://bit.ly/42zNb5hAbout SAPAs a global leader in enterprise applications and Business AI, SAP (NYSE: SAP) stands at the nexus of business and technology. For over 50 years, organizations have trusted SAP to bring out their best by uniting business-critical operations spanning finance, procurement, HR, supply chain, and customer experience. For more information, visit www.sap.com/hk.For more information, press only:Strategic Public Relations Group (SPRG)Andico TsuiEmail: andico.tsui@sprg.com.hkTel: 2114 4346 / 6902 3831 Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com
More
Nissin Foods Announces 2026 Q1 Financial Results ACN Newswire

Nissin Foods Announces 2026 Q1 Financial Results

Financial HighlightsFor the three months Ended 31 March 2026(HK$ million)20262025ChangeRevenue 1,115.61,071.9+ 4.1%Gross Profit402.1376.1+ 6.9%Gross Profit margin36.0%35.1%+ 0.9ppProfit attributable to owners of the Company122.4110.0+ 11.3%Net profit margin11.0%10.3%+ 0.7ppAdjusted EBITDA 209.0201.5+ 3.7%Earnings per share (HK cents)11.7310.54+ 11.3%HONG KONG, May 13, 2026 - (ACN Newswire via SeaPRwire.com) - Nissin Foods Company Limited (“Nissin Foods” or the “Company”, together with its subsidiaries, the “Group”; Stock code: 1475) today announced its unaudited first quarter financial results for the three months ended 31 March 2026 (the “Reporting Period”).The Group reported revenue of HK$1,115.6 million for the Reporting Period, representing an increase of 4.1% from HK$1,071.9 million of the corresponding period of 2025. Gross profit increased by 6.9% year-on-year to HK$402.1 million, due to the continued implementation of cost efficiency initiatives. Gross profit margin increased by 0.9 percentage points to 36.0% from 35.1% of the corresponding period of 2025 mainly attributable to the increased sales volume of the core brands to absorb cost pressure. Profit attributable to owners of the Company notably increased by 11.3% year-on-year to HK$122.4 million, while Adjusted EBITDA grew by 3.7% year-on-year to HK$209.0 million.Revenue from Hong Kong and other regions operations increased moderately by 3.1% due to the stable performance of the noodles business, particularly the Group’s core brands of Cup Noodles and Demae Iccho. As for the Chinese Mainland operations, revenue increased by 4.6% due to the sales expansion in the inland areas and the appreciation of Renminbi to Hong Kong Dollars.Mr Kiyotaka ANDO, Executive Director, Chairman and Chief Executive Officer of Nissin Foods, said, “Building on the solid momentum established in 2025, the Group delivered another quarter of resilient growth, with steady performance across our key markets. Revenue and profitability improved year-on-year, supported by stable sales volumes. Our core noodles business continued to perform well across regions, while our premiumisation and diversification strategies gained further traction in the Chinese Mainland. With a balanced regional footprint and enhanced operational execution, the Group remains well positioned to deliver sustainable growth and long-term value for shareholders.”About Nissin Foods Company LimitedNissin Foods Company Limited ("Nissin Foods”, together with its subsidiaries, the “Group”; Stock code: 1475) is a renowned food company in Hong Kong and the Chinese Mainland, with a diversified portfolio of well-known and highly popular brands, primarily focusing on the premium instant noodle segment. The Group officially established its presence in Hong Kong in 1984 and is the largest instant noodle company in Hong Kong. The Group primarily manufactures and sells instant noodles, high-quality frozen food products, including frozen dim sum and frozen noodles, and also sells and distributes other food and beverage products, including retort pouches, snacks, mineral water, sauce and vegetable products under its two core corporate brands, namely “NISSIN ” and “DOLL” together with a diversified portfolio of iconic household premium brands. The Group’s five flagship product brands, namely “Cup Noodles”, “Demae Iccho”, “Doll Instant Noodle”, “Doll Dim Sum” and “Fuku” are also among the most popular choices in their respective food product categories in Hong Kong. In the Chinese market, the Group has introduced technology innovation through the “ECO Cup” concept and primarily focuses its sales efforts in first- and second-tier cities. In addition, Nissin Foods operates business in other regions including Vietnam, Taiwan, Korea and Australia markets.Nissin Foods is currently a constituent of five Hang Seng Indexes, namely: Hang Seng Composite Index, Hang Seng Composite SmallCap Index, Hang Seng Composite Industry Index - Consumer Staples, Hang Seng SCHK Consumption Index and Hang Seng SCHK Consumer Staples Index. Nissin Foods is eligible for trading under Shanghai-Hong Kong and Shenzhen-Hong Kong Stock Connect. For more information, please visit www.nissingroup.com.hk. Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com
More
阿格妮特·柯克·克里斯蒂安森被任命为乐高基金会主席 ACN Newswire

阿格妮特·柯克·克里斯蒂安森被任命为乐高基金会主席

丹麦比隆, 2026年5月13日 - (亚太商讯 via SeaPRwire.com) - 在乐高基金会年度会议上,董事会选举阿格妮特·柯克·克里斯蒂安森担任董事会主席。作为乐高集团所有者柯克·克里斯蒂安森家族的第四代成员,她成为该基金会自1986年成立以来仅有的第五位主席。阿格妮特·柯克·克里斯蒂安森自2023年起担任乐高基金会副主席,此次接替其兄长托马斯·柯克·克里斯蒂安森出任主席,后者卸任后将担任副主席。除在乐高基金会的职务外,阿格妮特·柯克·克里斯蒂安森还担任家族控股及投资公司KIRKBI A/S的副主席,该公司持有乐高集团75%的股份。作为新任主席,阿格妮特·柯克·克里斯蒂安森强调了乐高基金会在为全球儿童创造更美好未来方面所发挥的作用:· “能够接任乐高基金会主席一职,并继续我们为儿童开展的重要工作,我深感荣幸。自40多年前成立以来,该基金会在我们家族中一直占据着非常特殊的地位。为儿童创造积极影响的深切责任感贯穿于我们家族的始终,我坚信每个孩子都应有机会茁壮成长。我为能为这一使命贡献力量并助力其传承而感到自豪。此次主席交接发生在阿格妮特接任非营利基金会“奥勒·柯克基金会”(Ole Kirk's Fond)主席一职的次年。随着这一交接,家族第四代成员正进一步拓展其参与范围,并致力于践行积极所有权。卸任主席托马斯·柯克·克里斯蒂安森表示:· 过去10年担任乐高基金会主席是我莫大的荣幸,如今能将这一职责移交给阿格妮特,我感到非常高兴。她对乐高基金会的使命怀有深切的热忱,我相信她将竭尽全力,为“保障所有儿童的童年”这一事业贡献力量。“在担任副主席期间,她为制定基金会当前的战略发挥了关键作用。随着她接任主席一职,我们将进一步扩大家族在整个乐高生态系统中的积极所有权和参与度。”托马斯·柯克·克里斯蒂安森自2016年起担任乐高基金会主席,在此期间,基金会通过全球合作伙伴组织承诺拨款超过150亿丹麦克朗(20亿欧元),致力于改善儿童福祉。· “40年来,乐高基金会始终致力于回馈社会,为儿童构建更美好的世界。我们深知家庭和社区对我们的信任,这份责任我们绝不轻视。即使在最艰难的环境中,基金会也能帮助孩子们展露笑颜,激励不同能力水平的学习者,并改变他们的人生轨迹。我们将以最敏锐的洞察力和最负责任的态度践行这一使命,”阿格妮特·柯克·克里斯蒂安森表示。作为乐高集团的股东之一,乐高基金会不仅致力于保障集团的持续发展与成功,更通过资助并紧密合作于Brac、IRC、联合国儿童基金会、救助儿童会、挪威难民理事会等组织,践行其慈善使命,支持教育、研究及儿童发展领域的各项倡议。乐高基金会董事会其他变动除阿格妮特与托马斯·柯克·克里斯蒂安森分别担任主席和副主席外,乐高基金会董事会还在5月的会议上选举英格丽德·斯坦格为董事会成员,她拥有丰富的慈善、教育及非营利组织领导经验。此外,乐高集团前首席执行官约尔根·维格·克努德斯托普(Jørgen Vig Knudstorp)以及红十字会与红新月会国际联合会前秘书长埃尔·哈吉·阿马杜·盖耶·西(El Hadji Amadou Gueye Sy,简称As),在为乐高基金会服务16年和4年后,分别离开了董事会。托马斯·柯克·克里斯蒂安森(Thomas Kirk Kristiansen)对两位离任的董事会成员长期以来对基金会的奉献表示感谢:· 我们非常期待欢迎英格丽德的加入,她将为董事会带来高度互补的专业知识。同时,我感谢阿斯(As)为我们提供了宝贵的见解和经验,帮助塑造了我们的工作。· 我还要向约尔根表达最诚挚的谢意,感谢他对基金会的坚定奉献。在任职期间,约尔根在制定我们的愿景和战略方面发挥了关键作用,同时始终没有忘记我们所服务的儿童。此外,自2021年起担任董事会成员的玛露·阿蒙德,接任了基金会第二副主席的职务。个人简介:阿格内特·柯克·克里斯蒂安森乐高基金会2026年 - 董事会主席2023年至2026年 - 董事会第二副主席2008年起 - 董事会成员KIRKBI A/S2024年 - 董事会副主席ADHD+中心,丹麦奥胡斯创始人奥勒·柯克基金会2025年 - 董事会主席学历2010年,奥胡斯大学心理学专业其他现任及曾任职务:· KIRK83 Holding ApS 执行经理· Ruca 顾问委员会成员· 乐高所有者家族第四代代表· 在家族企业、长期管理及董事会工作中拥有丰富经验乐高基金会董事会阿格内特·柯克·克里斯蒂安森 - 主席托马斯·柯克·克里斯蒂安森 - 第一副主席马洛·阿蒙德 - 第二副主席希拉里·彭宁顿 - 董事会成员英格丽德·斯坦格 - 董事会成员乐高基金会董事会主席1986 - 1993:戈特弗雷德·柯克·克里斯蒂安森(乐高第二代所有者)1993 - 2000:本特·斯科夫2000 - 2016:凯尔德·柯克·克里斯蒂安森(乐高第三代所有者)2016 - 2026:托马斯·柯克·克里斯蒂安森(乐高第四代所有者)2026 - 阿格妮特·柯克·克里斯蒂安森(乐高第四代所有者)关于乐高基金会:乐高基金会是一家丹麦企业基金会,受托持有乐高集团25%的股权。该基金会与全球合作伙伴携手,致力于满足儿童需求,捍卫童年的尊严。通过慈善捐赠和影响力投资,该基金会致力于为世界各地的每个孩子创造茁壮成长的条件和空间。有关乐高基金会的更多信息,请访问: https://www.legofoundation.com/ 联系方式:马德斯·赫维特·格兰德mads.hvitved.grand@legofoundation.com 来源:乐高基金会 Copyright 2026 亚太商讯 via SeaPRwire.com. All rights reserved. www.acnnewswire.com
More
日清食品公布2026年首季度业绩 ACN Newswire

日清食品公布2026年首季度业绩

财务撮要截至2026年3月31日止三个月(百万港元)20262025变动收入 1,115.61,071.9+ 4.1%毛利402.1376.1+ 6.9%毛利率36.0%35.1%+ 0.9个百分点本公司拥有人应占溢利122.4110.0+ 11.3%纯利率11.0%10.3%+ 0.7个百分点经调整EBITDA209.0201.5+ 3.7%每股盈利(港仙)11.7310.54+ 11.3%香港, 2026年5月13日 - (亚太商讯 via SeaPRwire.com) - 日清食品有限公司(「日清食品」或「公司」,连同其附属公司统称「集团」;股份代号:1475)今天公布截至2026年3月31日止三个月(「报告期」)之未经审核第一季度财务业绩。报告期内,集团录得收入1,115.6百万港元,较2025年同期的1,071.9百万港元增加4.1%。毛利按年上升6.9%至402.1百万港元,主要由于持续实施成本效益措施所致。毛利率由2025年同期的35.1%增加0.9个百分点至36.0%,主要由于核心品牌销量增加,消化了成本压力。本公司拥有人应占溢利录得122.4百万港元,按年显著上升11.3%;经调整EBITDA则按年增长3.7%至209.0百万港元。来自香港及其他地区业务的收入增加3.1%,此乃由于面类业务表现稳健,特别是集团核心品牌合味道及出前一丁。内地业务收入增加4.6%,主要受惠于内陆地区的销售扩大及人民币兑港元升值所致。日清食品执行董事、董事长兼首席执行官安藤清隆先生表示:「延续2025年建立的良好增长势头,集团于本季度持续录得稳健的业务表现,主要市场的营运表现保持平稳。收入及盈利按年有所提升,主要受稳定的销售量所支持。核心方便面业务于各地区持续表现理想,而高端化及多元化策略亦于中国内地进一步取得成效。凭借均衡的地域布局及持续提升的营运执行力,集团有信心为股东创造可持续的长远价值。」有关日清食品有限公司日清食品有限公司(「日清食品」,连同其附属公司统称「集团」;股份代号:1475)为一间在中国内地及香港知名的食品公司,主要专营优质方便面市场,旗下众多品牌不仅知名度高,且广受顾客喜爱。集团于1984年正式于香港设立营业据点并为香港最大的方便面公司。集团主要生产及销售两个核心企业品牌「日清」及「公仔」,以及多元化的家庭食品品牌组合,出品具标志性和优质的方便面、优质冷冻食品(包括冷冻点心及冷冻面条)并销售和分销其他食品及饮料产品(包括蒸煮袋装产品、零食、矿泉水、酱料及蔬菜产品)。集团五个旗舰品牌「合味道」、「出前一丁」、「公仔面」、「公仔点心」及「福」在香港亦是其各自食品类别中最受欢迎的选择。中国内地市场方面,集团以创新技术推出「ECO杯」概念,销售活动主要集中在中国内地的一线及二线城市。此外,日清食品在其他地区开展业务,包括越南、台湾、韩国及澳洲市场。日清食品被纳入5项恒生指数,包括恒生综合指数、恒生综合小型股指数、恒生综合行业指数-必需性消费、恒生港股通消费行业指数和恒生港股通食品饮料消费指数。日清食品现可通过沪港通及深港通下港股通进行交易。详情请浏览www.nissingroup.com.hk。 Copyright 2026 亚太商讯 via SeaPRwire.com. All rights reserved. www.acnnewswire.com
More